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Model Structure 
Microsimulation Model in Cancer of the Bowel (MiMiC-Bowel) is an individual patient simulation 
model built in the R programming language, which has been designed to enable comparison of the 
effectiveness, cost-effectiveness and resource use of different personalised screening and 
surveillance strategies for colorectal cancer (CRC). The model simulates the life course of patients 
representing the population of England, who each have a set of individual characteristics which 
determines their cancer risk and response to screening and surveillance. The model has a lifetime 
horizon and takes an NHS perspective. 
Underpinning the model is a CRC natural history module with nine mutually exclusive health states: 
Normal Epithelium; Low Risk Adenoma; High Risk Adenoma; CRC Dukes Stage A; CRC Dukes Stage B; 
CRC Dukes Stage C; CRC Dukes Stage D; CRC Death; Other Cause Death. In each time cycle of the 
model (set to one year as default) individuals have the probability of transitioning between health 
states as shown in Figure 1. Only one transition is possible within each time cycle. Low and high-risk 
adenoma health states are defined using the British Society of Gastroenterology (BSG) guidelines for 
endoscopic surveillance following adenoma removal 1. The high-risk adenoma health state includes 
persons with at least 3 small adenomas or at least one adenoma of size >1cm. The low-risk adenoma 
health state includes persons with 1-2 small (<1cm) adenomas. This means that the model does not 
simulate progression of individual adenomas, instead taking the perspective of an individual’s overall 
risk without having to define their exact status in terms of number, size and type of adenomas. Most 
CRC develops through adenomas; however, there is thought to be some development of CRC 
through serrated pathways, which is also reflected in the model structure by transition from normal 
epithelium directly to CRC. 
Figure 1: Structure of the CRC natural history model health states 
 
Once an individual develops CRC, they have a probability of progressing to the next stage. At each 
stage there is a probability that the individual will be diagnosed either through screening, 
surveillance or via symptomatic/chance presentation. Diagnosed CRC is not represented as a 
separate set of mutually exclusive health states in the model, but is flagged separately. This means it 
is possible for an individual to both progress to the next health state and be diagnosed within a 
single model cycle. However, it is assumed that CRC stops progressing after diagnosis. After CRC 
diagnosis individuals are also no longer eligible for the modelled screening and surveillance 
pathways, instead following a disease pathway which includes treatment costs, utility reductions 
and reduced survival compared to the general population. 
The model has two absorbing states. Whilst all individuals have a probability of dying from other 
causes, only those with CRC can die from CRC. It is possible to die from CRC Stage D in the model 
without prior diagnosis. In this case it is assumed that individuals are diagnosed within the same 
time cycle (i.e. just before or after death). It is also possible that individuals can die from CRC Stage D 
but are never diagnosed. It is assumed that this probability increases with age. In this case it is 
assumed that their death would be recorded as due to other causes, and therefore this is modelled 
through transition to other cause mortality. 
The screening, surveillance and symptomatic diagnosis modules of the model sit on top of the 
natural history model and feed into it (see Figure 2). Two types of screening are modelled; flexible 
sigmoidoscopy (FS) and Faecal Immunochemical Test (FIT), together with further investigation using 
colonoscopy or computerised tomography colonography (CTC). Whilst the screening and 
surveillance pathways are hard coded (see Screening and Surveillance sections for details), the 
model allows flexible specification of eligibility criteria, enabling a large number of different 
screening strategies, including personalised strategies, to be easily modelled. 
Figure 2: Model structure diagram showing how information feeds across the different model 
modules  
 
Following model setup, the model simulation progresses by first evaluating the natural history 
transitions that happen in that cycle (Figure 3). The next step is to decide who is diagnosed with CRC 
symptomatically, then if screening is selected, the screening and surveillance modules of the model 
are run. Finally, model outcomes are gathered. The process is repeated each cycle until the model 
time horizon is reached. In each model cycle, each individual may accumulate costs (from resource 
use related to screening and cancer treatment) and utility decrements (due to age, screening harms 
and cancer diagnosis). Costs, QALYs and other outcomes such as resource use and cancer cases are 
aggregated; half cycle correction and discounting is applied to costs, QALYs and life years, and 
incremental results are estimated.  
Figure 3: Model process diagram showing the order that events happen in the model 
 
The model can be run in various different modes including Deterministic, PSA, Calibration and 
Testing modes. These enable users to choose between different types of inputs and outputs 
reflecting the different model functions. Deterministic, Calibration and Testing modes all use mean 
parameter values in every model loop, whilst the PSA mode enables a user-defined number of 
random samples to be taken from each parameter distribution and used sequentially in model loops. 
Users can also separately decide the number of model loops that they wish to run. 
In terms of outputs, the Deterministic mode produces a single results table saving only outputs 
aggregated over the entire population, which maximises model speed and efficiency. In addition to 
this, the PSA mode produces a table of key results for each PSA loop. The Calibration mode only 
produces results that are relevant to calculating CRC and adenoma incidence and mortality, whilst 
the Testing mode produces a wide range of outputs including individual health state transitions, 
individual screening history and individual costs and utilities to enable thorough testing of model 
function.  
Model Population 
Baseline Phenotypic Characteristics 
The model baseline population is composed of individuals from the Health Survey for England (HSE) 
2014 2, an annual survey which is designed to provide a snapshot of the nation’s health. Individuals 
aged under 30 were excluded from the model as it was assumed that no individuals aged under 30 
would have yet developed adenomas or CRC. This resulted in a sample of 6,787 individuals. The 2014 
sample was chosen as this was the most recent that included estimates of health-related quality of 
life using EuroQol - 5 Dimensions (EQ-5D) 3. Other individual phenotypic attributes extracted from 
HSE 2014 for use in the model included age, sex, ethnicity, indices of multiple deprivation (IMD) 
quintile (a measurement of socioeconomic deprivation), smoking status, body mass index (BMI), 
physical activity (measured in weekly metabolic equivalents [METS]), alcohol consumption 
(measured in weekly units) and the individual survey weights. The survey weights have been 
calculated by the HSE to enable adjustment of the sample so that it matches national population 
estimates of age, sex and regional distribution, correcting for non-response, and thereby making the 
sample more representative of the English population. Given that the model is used to estimate 
resource use in the English population, it was essential that the survey weights were included in 
model outcomes. Table 1 summarises the individual characteristics extracted from HSE 2014. 
Table 1: Summary of individual characteristics extracted from HSE 2014 2, their coding in the model 
and the numbers with missing data. 
Characteristic 
(Unit) 
HSE 2014 
Survey Code 
How Coded in the Model Number with 
Missing Data 
Age (Years) Age90 Continuous integer 0 
Sex Sex Binary; 1 = Male, 0 = Female. 0 
Ethnicity origin2 Numeric; 1 = white; 2 = black; 3 = Asian; 4 = 
mixed; 5 = other 
27 
IMD Quintile qimd Numeric: 1 = least deprived; 5 = most 
deprived. 
0 
BMI (kg/m2) BMIval Continuous variable 953 
Smoking Status cigsta3 Split into two binary variables: Current 
Smoker (1 = yes; 0 = no); Former Smoker (1 = 
yes; 0 = no). 
20 
Alcohol Intake 
(Weekly Units) 
totalwu Continuous variable. 92 
Physical Activity 
(Weekly METS) 
TotmModWk 
TotmVigWk 
Single continuous variable calculated by 
combining minutes of moderate activity (4 
METS per minute) and vigorous activity (8 
METS per minute). 
1070 
996 
EQ-5D Mobility 
Selfcare 
UsualAct 
Pain 
Anxiety 
EQ-5D score calculated from responses to 
each question using UK value sets generated 
through time trade-off valuation 3. 
751 
772 
758 
755 
767 
weighting wt_int Continuous variable. 0 
HSE = Health Survey for England; IMD = Indices of Multiple Deprivation; BMI = Body Mass Index; 
EQ-5D = EuroQol 5 dimensions. 
 
Missing Data for Phenotypic Characteristics 
Values were missing for some of the variables in some individuals. For some of the variables with 
small numbers of missing data it was assumed that those with missing data belonged to the largest 
group. Therefore, it was assumed that those missing ethnicity data were white and those missing 
smoking data were never regular smokers. It was also assumed that individuals with missing physical 
activity data for either moderate or vigorous activity did not do any moderate or vigorous activity. 
Individuals with missing data for both of these categories were assumed to be inactive. 
For those missing data about alcohol consumption, data from an additional HSE variable called 
‘dnevr’ was used, representing whether an individual had always been a non-drinker. Those who had 
answered either that they had never been a drinker, or had previously been a drinker but stopped 
were assumed to drink zero units per week. All others with missing consumption data were assumed 
to drink the average weekly number of units drank by other alcohol drinkers in HSE 2014, which was 
12.77. 
A large number of individuals were missing data about one or more of the EQ-5D dimensions, 
meaning that their EQ-5D could not be calculated. To estimate these values, EQ-5D for all other 
individuals was calculated and a linear regression was performed using age, sex and IMD quintile as 
explanatory variables to predict EQ-5D (Table 2), given that all individuals had data for these three 
variables. All three coefficients were very highly significant (P = <0.0001) and adjusted R2 was 0.37 
indicating that 37% of the differences between individuals could be explained by these three 
variables. EQ-5D was then imputed for individuals with missing data using these variables. 
Table 2: Linear regression coefficients used to calculate missing EQ-5D values 
Coefficients Mean Standard Error 
Intercept 1.1041305 0.0172774 
Age -0.0036214 0.0002317 
Sex 0.0335711 0.0081017 
IMD Quintile -0.0282924 0.0028597 
 
A similar approach was used to estimate BMI in those with missing data about BMI (Table 3). In this 
case the only significant variable was IMD quintile. Sex was not significant and its removal improved 
the model. Age was significant but its removal reduced the predictive ability of the model so this was 
left in. Adjusted R-squared was only 0.06. However, the F statistic was highly significant indicating 
that the model was better at predicting BMI than just using the intercept (i.e. mean BMI value) 
alone. BMI was then imputed for individuals with missing data using these variables. 
Table 3: Linear regression coefficients used to calculate missing BMI values 
Coefficients Mean Standard Error 
Intercept 26.761749 0.381804 
Age 0.005334 0.005242 
IMD Quintile 0.288154 0.065263 
 
Modelling Changes in Phenotypic Characteristics by Age 
Several of the characteristics included in the baseline modelled population will change as a person 
ages. These include EQ-5D, BMI, alcohol consumption, physical activity levels and smoking status. 
Accurate modelling of individual level changes in these factors is extremely complex, but a simple set 
of methods was sought in order to be able to approximate changing risk and health benefits over 
time. 
Continuous Risk Factors (BMI, Alcohol Consumption and Physical Activity) 
A percentile method was used to model trajectories of continuous risk factors by age. Plots showing 
the mean BMI, physical activity (measured in weekly METS) and alcohol consumption (measured in 
weekly units) for each decile of the HSE 2014 population indicate that there are clear trends that it 
would be important to reflect in risk modelling (Figure 4, Figure 5 and Figure 6). Note that these 
population trends are unlikely to correlate exactly with individual level trajectories for two reasons. 
Firstly, unhealthy people (e.g. those with very high BMI, high alcohol consumption and low physical 
activity) are likely to die earlier which will shift all deciles down/up slightly compared to individual 
level trajectories. Secondly, population trends also include birth cohort differences due to social 
changes over time. This may have particular impact for the alcohol consumption trends as it is 
known that alcohol consumption has been falling amongst young people in recent years 4. 
Figure 4: Mean BMI for each decile of the HSE 2014 population 2 
 
Figure 5: Mean Physical Activity METS per week for each decile of the HSE 2014 population 2 
 
Figure 6: Mean alcohol units per week for each decile of the HSE 2014 population 2 
 
The percentile method was implemented in the model by assigning each person to the relevant 
decile for BMI, physical activity and alcohol units based on the surveyed values for these 
measurements at their surveyed age. BMI, physical activity and alcohol units for each individual 
were then altered to follow the trajectory corresponding to the relevant decile and current age of 
the individual in the model. Using deciles rather than smaller percentiles does mean that some 
individual level variation is removed from the model (i.e. everyone follows one of 10 predefined 
trajectories); however, this was constrained by the relatively small sample size of HSE 2014, to 
reduce the amount of noise in the trajectories. 
Smoking 
Data from HSE 2014 indicates that the number of current smokers reduces by age, whilst the 
number of former smokers increases, indicating that there is a general trend for smoking cessation 
from the age of 30. It would therefore be reasonable to assume that no individuals who were 
surveyed as non-smokers in HSE 2014 would start smoking after the age of 30. 
Modelling a change in a binary factor is complex, particularly in a multi-age model, but is likely to 
have little impact on the performance of risk models given that the difference in relative risk of CRC 
between current and former smokers is small (see the Modelling Individual Cancer Risk section). The 
trend for current smokers to become past smokers as they age was therefore not implemented in 
this version of the model; however, it may be incorporated into future model versions. 
Figure 7: The proportion of current and former smokers by age in the HSE 2014 population 2 
 
EQ-5D 
EQ-5D decreases with age, therefore age decrements were applied to each individual’s baseline EQ-
5D score reflecting their current age in the model, compared with their baseline age. It was assumed 
that age-related decrements were constant over time. The size of this decrement was calculated 
using data from a study that pooled several years of HSE data to estimate general population values 
of EQ-5D by age 5. Annual age decrement was calculated as the difference between EQ-5D score at 
ages 80-84 and 30-34, divided by 50, which resulted in a change of -0.00432 (95% CI: -0.00460; -
0.00404) for each additional year of age. This process was used both to reduce EQ-5D as individuals 
age beyond their surveyed age, and to increase EQ-5D in the cohort version of the model where 
individuals all start at age 30, which may be considerably younger than their surveyed age. EQ-5D at 
younger ages was constrained to a maximum of 1. 
 
Genetic Characteristics 
HSE 2014 does not contain any information about genetic characteristics. Huyghe and others (2019)6 
described identification of over 40 new genetic risk variants for CRC, using data from genome-wide 
small nucleotide polymorphism (SNP) genotyping of over 125,000 different individuals. When 
combined with previously reported risk variants, this resulted in 120 CRC risk loci with estimated per 
allele log odds ratios.  
Information about the frequency of each risk allele in the English population was obtained from UK 
Biobank 7, which also provided information about the correlation between risk alleles on each 
chromosome. Each individual from HSE 2014 was randomly assigned a continuous dosage of each 
risk allele between zero and two (corresponding to zero, one or two copies of the risk allele at a 
locus, and equivalent to the output from a genetic imputation algorithm), taking into account the 
correlations between risk alleles on the same chromosome, but assuming independence between 
risk alleles on different chromosomes and between genetic and phenotypic characteristics. This is 
because no data was available on correlation between genetic and phenotypic characteristics. 
Family History 
HSE 2014 does not contain any information about family history of CRC, which is a risk factor for CRC 
and included in many risk models. Family history of CRC can be defined in different ways, but for the 
purposes of this model was defined as having one or more first-degree relatives who had been 
previously diagnosed with CRC. Information about family history of CRC was obtained from UK 
Biobank 7. Family history is correlated with age (Figure 8); however, it would be incorrect to model 
individual risk levels changing over time due to changes in family history, when in fact it is the 
knowledge about familial risk that changes, not the risk itself. Instead, two different family history 
variables were modelled corresponding to true family history and known family history, with true 
family history used to influence modelled natural history of CRC and known family history used to 
calculate CRC risk in risk models. For both of these family history at a given age was estimated 
through fitting a linear model to all data points between the 36-40 and 56-60 age groups from the 
UK Biobank data (intercept = -0.07266 [95% CI: -0.083 to -0.0616] and age coefficient = 0.00337 
[95% CI: 0.0035 to 0.0032]).  
True family history was assigned randomly to 12.9% of individuals, corresponding to the proportion 
estimated to have a family history aged 60. Age 60 was chosen to represent the average age at 
which the familial relative risk for CRC used in the model had been calculated (see Modelling 
Individual Cancer Risk section). Known family history was assigned to a subset of those individuals 
with true family history, corresponding to the age at which a risk model might be used to estimate 
CRC risk (ranging between age 30 and 60, depending upon model user input). Individuals were 
randomly assigned to having family history as no evidence was available to correlate family history 
with other characteristics already included in the model.  
Figure 8: Graph showing increase in family history of CRC with age, from UK Biobank 7 
 
 
Single-Aged Cohort versus Multi-Aged Cohort 
The model was set up to enable a single-aged cohort to be modelled, in order to answer cost-
effectiveness questions. A starting age of 30 was chosen, as it could be assumed that all individuals 
aged 30 would be in the normal epithelium health state (in reality a very small percentage may have 
adenomas or CRC, but these individuals are likely to represent those with rare monogenic conditions 
predisposing them to CRC). The cohort was created by artificially setting the ages of all individuals 
from HSE 2014 to 30. At the same time, adjustments were made to individual BMI, alcohol 
consumption, physical activity and EQ-5D to reflect the change in age, based on the methods 
described above. Summary statistics for this population are shown in Table 4. The cohort was 
modelled over their lifetime to provide estimates of cost-effectiveness for fully rolled out screening 
strategies.  
For resource use questions, it is essential that the baseline population should represent the current 
population of England, i.e. a multi-aged cohort. In theory, this can be approximated using the HSE 
2014 population with survey weights (Table 4). Because baseline individuals start at a range of 
different ages, it would be necessary to simulate a starting health state for each individual, rather 
than assuming all individuals were in normal epithelium. This functionality has not yet been added to 
the model, but will be available in future model versions. 
Table 4: Summary statistics for the model population at baseline, for multi-aged and single-aged 
cohorts. All characteristics come from HSE 2014 2 apart from probability of family history, which 
comes from UK Biobank 7. 
Characteristic Mean (HSE 
2014) 
Standard 
Deviation 
Weighted Mean 
at Multi-Aged 
Cohort Model 
Start  
Weighted Mean 
at Single-Aged 
Cohort Model 
Start (Age 30) 
Age (years) 55.2 15.5 53.9 30 
BMI (kg/m2) 28.0 4.9 27.9 27.0 
Alcohol Consumption 
in Drinkers (units/wk) 
12.8 21.2 12.9 10.0 
Physical Activity in the 
Active (METS/wk) 
4621.8 6685.9 4560.4 5230.6 
EQ-5D Score 0.841 0.227 0.847 0.950 
 Number in 
HSE 2014 
Percentage in 
HSE 2014 
Weighted 
Percentage 
(Multi-Aged 
Cohort) 
Weighted 
Percentage 
Single-Aged 
Cohort) 
Male 3011 44.4% 48.3% 48.3% 
Ethnicity: White 6105 90.0% 88.6% 88.6% 
Ethnicity: Asian 395 5.8% 6.8% 6.8% 
Ethnicity: Black 164 2.4% 2.6% 2.6% 
IMD1 1546 22.8% 22.3% 22.3% 
IMD2 1424 21.0% 20.9% 20.9% 
IMD3 1346 19.8% 19.7% 19.7% 
IMD4 1289 19.0% 19.7% 19.7% 
IMD5 1182 17.4% 17.4% 17.4% 
Current Smoker 1134 16.7% 17.4% 17.4% 
Former Smoker 1909 28.1% 27.7% 27.7% 
Non drinker 1158 17.1% 17.2% 17.2% 
Non active 2888 42.6% 41.4% 41.4% 
Family History Age 30 NA NA 2.8% 2.8% 
Family History Age 35 NA NA 4.5% 4.5% 
Family History Age 40 NA NA 6.2% 6.2% 
Family History Age 45 NA NA 7.9% 7.9% 
Family History Age 50 NA NA 9.6% 9.6% 
Family History Age 55 NA NA 11.3% 11.3% 
Family History Age 60 
(known family history) 
NA NA 12.9% 12.9% 
  
CRC Natural History  
Calibration of unobservable parameters 
The natural history module of the model relies upon transitions between the 9 health states as 
shown in Figure 1, in addition to parameters for symptomatic/chance diagnosis. Transition 
probabilities cannot be directly observed, so are usually obtained through calibration against target 
data that can be observed.  
The model calibration fitted to several observed data sets: low-risk adenoma prevalence, high-risk 
adenoma prevalence, undiagnosed CRC, and CRC incidence. The calibration also applied two 
dependent data sets: diagnosed CRC by stage at diagnosis and undiagnosed CRC by stage. Because of 
data unavailability, only CRC incidence data were retrieved from English sources 8. The prevalence of 
low- and high risk adenoma and undiagnosed CRC in the population was estimated from the 
detection rates of lesions by single colonoscopy screening reported in the large population German 
study reported by Brenner (2013, 2014)9-11 adjusted by colonoscopy sensitivity and relative 
prevalence of advanced versus high risk adenomas12-14.  
Transition between precancerous health states:  Normal epithelium->Low risk adenoma; Low risk 
adenoma->high risk adenoma; high risk adenoma-> CRC_Dukes’ A; Normal Epithelium-> CRC_Dukes’ 
A (estimated separately for males and females to represent differing CRC incidence). 
CRC stage progression: CRC Dukes’ A -> CRC Dukes’ B; CRC Dukes’ B -> CRC Dukes’ C; CRC Dukes’ C -> 
CRC Dukes’ D 
CRC symptomatic diagnosis: CRC Dukes’ A -> CRC Dukes’ A diagnosed; CRC Dukes’ B -> CRC Dukes’ B 
diagnosed, CRC Dukes’ C -> CRC Dukes’ C diagnosed; CRC Dukes’ D -> CRC Dukes’ D diagnosed 
The main assumptions of the calibration process were the following:  
 Pre-cancer transitions and transitions to CRC are assumed to be sex and age-specific, while 
transitions between CRC stages and symptomatic presentation rates are assumed to be age and sex 
independent due to a lack of data to confirm otherwise. 
 15% of CRC cases among men and 15% of CRC cases among women are assumed to develop 
through the serrated neoplastic pathway, this rate was reported in the British Society of 
Gastroenterology position statement 15. 
 The first cases of CRC in England in 200516 were among 15-19 years old, so it was assumed 
that the transition probability from normal epithelium to CRC stage A at age 15 is equal to zero and 
that it linearly increases to a maximum value at age 100 years. The transition rate at age 100 was 
determined within the first stage of the calibration process. 
 The annual probability that an individual is diagnosed increases with more advanced cancer 
stage. The probability of diagnosis at stages CRC A and B was assumed to be lower in older people 
who are more likely to have other comorbid conditions, so an age-related linear decrement in the 
probability of diagnosis was applied to individuals aged over 75. 
Calibration process 
The calibration used the Metropolis–Hastings algorithm to estimate the posterior probability 
distributions of model parameters. The starting parameter set was manually calibrated to receive an 
approximate fit to all independent data targets. For each data set, a measure of model fit was 
calculated as the sum squared error (SSE) between the model predictions (scaled to the same 
population size as the target data set) and the observed data. The objective function which we aim 
to minimise includes the total SSE from each of the target data sets. The SSE for each target data 
sets was adjusted by dividing by variance.  A parameter epsilon was used to determine the 
maximum step size for each iteration of the algorithm. The epsilon value was set to 10% of the 
parameters values. As the algorithm converges on the solution parameter set it is efficient to reduce 
the maximum step size. This tuning was achieved by using an epsilon multiplier, which was initially 
set to one and subsequently decreased by 20% if during the last 25 calibration cycles two or less 
parameter sets were accepted.  The probability of accepting a proposal set which increases the 
objective function by more than 5 is less than 10%.  
Calibration outcomes 
The calibration approach applied, allowed a good fit to each of the four main data sets (Figure 9 to 
Figure 14). 
Figure 9: Prevalence of low-risk adenoma predicted by the model and target data 
  
Figure 10: Prevalence of high-risk adenoma predicted by the model and target data 
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Figure 11: Prevalence of CRC predicted by the model and target data 
 
Figure 12: Incidence of CRC predicted by the model and target data 
 
 
 
0
500
1000
1500
2000
2500
30 40 50 60 70 80 90
Pr
e
va
le
n
ce
 p
er
 
10
0,
00
0 
po
pu
la
tio
n
Age, years
CRC prevalence – male, MiMiC model predictions
CRC prevalence – female, MiMiC model predictions
CRC prevalence – calibration target
0
100
200
300
400
500
30 40 50 60 70 80 90In
ci
de
nc
e
 p
er
 
10
0,
00
0 
po
pu
la
tio
n
Age, years
CRC incidence – male, MiMiC model predictions
CRC incidence – female, MiMiC model predictions
CRC incidence – calibration target
Figure 13: Incidence of CRC by stage among males predicted by the model and target data 
  
Figure 14: Incidence of CRC by stage among females predicted by the model and target data 
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The calibrated values of the parameters are reported in Table 5.  
Table 5: Calibrated parameter values 
Parameter Calibrated 
Mean Value 
Transition probability from normal epithelium to low-risk adenoma, male, age 37 0.0020 
Transition probability from normal epithelium to low-risk adenoma, male, age 47 0.0268 
Transition probability from normal epithelium to low-risk adenoma, male, age 57 0.0149 
Transition probability from normal epithelium to low-risk adenoma, male, age 67 0.0082 
Transition probability from normal epithelium to low-risk adenoma, male, age 77 0.0044 
Transition probability from normal epithelium to low-risk adenoma, male, age 87 0.0032 
Transition probability from low-risk adenoma to high-risk adenoma, male, age 37 0.0282 
Transition probability from low-risk adenoma to high-risk adenoma, male, age 47 0.0313 
Transition probability from low-risk adenoma to high-risk adenoma, male, age 57 0.0206 
Transition probability from low-risk adenoma to high-risk adenoma, male, age 67 0.0121 
Transition probability from low-risk adenoma to high-risk adenoma, male, age 77 0.0155 
Transition probability from low-risk adenoma to high-risk adenoma, male, age 87 0.0093 
Transition probability from high-risk adenoma to colorectal cancer, male, age 37 0.0092 
Transition probability from high-risk adenoma to colorectal cancer, male, age 47 0.0163 
Transition probability from high-risk adenoma to colorectal cancer, male, age 57 0.0181 
Transition probability from high-risk adenoma to colorectal cancer, male, age 67 0.0284 
Transition probability from high-risk adenoma to colorectal cancer, male, age 77 0.0502 
Transition probability from high-risk adenoma to colorectal cancer, male, age 87 0.0352 
Transition probability from normal epithelium to low-risk adenoma, female, age 37 0.0012 
Transition probability from normal epithelium to low-risk adenoma, female, age 47 0.0162 
Transition probability from normal epithelium to low-risk adenoma, female, age 57 0.0115 
Transition probability from normal epithelium to low-risk adenoma, female, age 67 0.0083 
Transition probability from normal epithelium to low-risk adenoma, female, age 77 0.0040 
Transition probability from normal epithelium to low-risk adenoma, female, age 87 0.0030 
Transition probability from low-risk adenoma to high-risk adenoma, female, age 37 0.0175 
Transition probability from low-risk adenoma to high-risk adenoma, female, age 47 0.0285 
Transition probability from low-risk adenoma to high-risk adenoma, female, age 57 0.0145 
Transition probability from low-risk adenoma to high-risk adenoma, female, age 67 0.0144 
Transition probability from low-risk adenoma to high-risk adenoma, female, age 77 0.0199 
Transition probability from low-risk adenoma to high-risk adenoma, female, age 87 0.0114 
Transition probability from high-risk adenoma to colorectal cancer, female, age 37 0.0047 
Transition probability from high-risk adenoma to colorectal cancer, female, age 47 0.0208 
Transition probability from high-risk adenoma to colorectal cancer, female, age 57 0.0272 
Transition probability from high-risk adenoma to colorectal cancer, female, age 67 0.0359 
Transition probability from high-risk adenoma to colorectal cancer, female, age 77 0.0650 
Transition probability from high-risk adenoma to colorectal cancer, female, age 87 0.0531 
Transition probability from normal epithelium to colorectal cancer 0.0006 
Annual decrement in symptomatic cancer A,B presentation among people older 
than 75 years 
0.0361 
Probability of death undiagnosed at stage D 0.0400 
Transition probability from colorectal cancer stage A to stage B 0.2932 
Transition probability from colorectal cancer stage B to stage C 0.5539 
Transition probability from colorectal cancer stage C to stage D 0.3500 
Probability of being symptomatic, colorectal cancer stage A 0.0203 
Probability of being symptomatic, colorectal cancer stage B 0.1429 
Probability of being symptomatic, colorectal cancer stage C 0.2741 
Probability of being symptomatic, colorectal cancer stage D 0.2500 
  
Modelling Individual Cancer Risk 
Modelling Individual Cancer Risk for Natural History Transitions  
Individualised cancer risk, based on phenotypic and genetic risk factors beyond that conferred by 
age and sex, was incorporated into the model through modification of the first transitions from 
normal epithelium to low risk adenoma (representing the adenoma-carcinoma pathway) and from 
normal epithelium to CRC Stage A (representing the serrated pathway). This approach was used for 
two reasons. Firstly, modification of a single transition probability rather than all three transitions 
leading to CRC through the adenoma-carcinoma pathway simplified the process of incorporating 
individual cancer risk considerably. Secondly, the evidence from Brenner et al (2013/2014 indicates 
that male/female differences in transition probabilities are only significant for the first transition 9 10, 
suggesting that differences in CRC risk are implemented through differences in adenoma risk. It 
appeared to be a reasonable assumption that this could be extended to differences in risk due to 
other characteristics. There is no information about how phenotypic and genetic risks impact on the 
serrated pathway compared with the adenoma-carcinoma pathway. However, it seems biologically 
plausible that the same risk factors could apply to both pathways, so it was assumed in the model 
that risk factors acted equally on both transitions. 
Modelling genetic risk for natural history transitions 
It was assumed that an individual’s true genetic risk of CRC was represented by all the risk alleles 
known about to date; i.e. the 120 alleles described in Huyghe et al (2019) 6. Genetic risk for each 
individual was calculated as the sum of the per allele log odds ratio estimates for each of the 120 
genetic risk loci multiplied by the dosage for each of the simulated risk alleles.  
prs = є(allele.freq * allele.logOR) 
Where prs = individual genetic risk score, allele.freq = dosage for each of the simulated risk alleles, 
allele.logOR = per allele log odds ratio estimate for each of the simulated risk alleles. 
Individual genetic risk was then standardised by subtracting the population weighted mean genetic 
risk score and dividing by the weighted risk score standard deviation as follows:  
stprs = (prs - wtdmean(prs)) / wtdsd(prs) 
Where stprs = individual standardised genetic risk score, prs = individual genetic risk score, 
wtdmean(prs) = weighted population mean of the genetic risk score and wtdsd(prs) = weighted 
population standard deviation of the genetic risk score. 
This was then converted into an individual relative risk using the following equation: 
Individual RR = exp (wtdsd(prs) * stprs) 
where stprs = individual standardised genetic risk score and wtdsd(prs) = weighted population 
standard deviation of the (non-standardised) genetic risk score. 
Modelling phenotypic risk for natural history transitions 
Relative risks for CRC relating to a range of different environmental risk factors were obtained from 
a recent study by Brown et al (2014) 17 calculating the fraction of cancer attributable to modifiable 
risk factors in the UK (Table 6). Risk factors for CRC included smoking, alcohol consumption, (lack of) 
physical activity, red meat consumption, (lack of) fibre consumption and BMI. The study looked at 
some other risk factors (e.g. air pollution, occupation, infections, radiation and oral contraceptives), 
but no data was found relating to these for CRC. Modifiable risk factors incorporated in the model 
were those for which information was available in HSE 2014 2; i.e. smoking, alcohol consumption, 
physical activity and BMI. Neither fibre nor red meat consumption were detailed in HSE 2014 and no 
simple method was available for imputing these from other HSE 2014 characteristics, so these were 
not included in the modelled CRC risk estimates.  
In addition to these modifiable phenotypic risk factors, family history of CRC and ethnicity were also 
included in phenotypic risk. Individuals having one or more first-degree relatives previously 
diagnosed with CRC have been found to have a risk of CRC that is around 2.2 fold greater than those 
without family history 18. Family history is likely to occur through a mixture of shared genetics and 
shared environment. The proportion of familial relative risk already accounted for by the Huyghe et 
al (2019) genetic risk factors described above was estimated in that study as 11.9% 6. To avoid 
double counting, familial risk was adjusted to remove this genetic component, resulting in a relative 
risk of 2.003. No evidence was available to inform the proportion of familial risk arising from each of 
the modifiable risk factors already incorporated in the model, so no further adjustments to familial 
risk were made. 
Ethnic differences in CRC incidence in England are very large, with most minority ethnic groups 
having a much lower risk of CRC than the white population. It is thought that this is likely to be 
partially due to differences in diet between white and non-white populations, but may also be 
partially genetic. Differences in risk by ethnic groups (white, black, south Asian and other) were 
taken from QCancer research 19, which is based on English primary care data. Data for each ethnic 
group used in the model was combined using a weighted average as follows: black = black African 
and Caribbean; Asian = Indian and Pakistani and Bangladeshi and other Asian; Other = Chinese and 
Other. 
In order to ensure that the overall risk in the modelled population remained unchanged (i.e. product 
of all relative risks equals 1), it was necessary to adjust relative risks for each risk factor using the 
following equation: 
Individual RR = Unit RR (from Table 6) ^ (Individual Value  - Population Average Value) 
Where individual value is the HSE 2014 data entry for that individual, by unit stated in Table 6, and 
population average value is the mean, weighted value in the HSE 2014 sample.  
For binary characterisics (e.g. current smoker), the individual value was considered to be 1 for an 
individual possessing that characteristics, and 0 for an individual not possessing that characteristics, 
with the population mean value representing the proportion of current smokers in the population. 
Individual relative risks for each phenotypic risk factor were multiplied together to produce a 
personalised risk of CRC due to phenotypic risk factors. This was then multiplied by each person’s 
individual genotypic risk to produce an overall personalised relative risk of CRC for each modelled 
individual. For each individual, a personalised probability of transition from normal epithelium to 
low risk adenoma, or from normal epithelium to CRC stage A was calculated by multiplying their 
personalised relative risk by the relevant calibrated age and sex specific transition probability. 
Calibration of relative risks for natural history transitions 
Relative risks described above represent the lifetime relative risk of CRC. However, application of the 
relative risks at the level of the transitions from normal epithelium to low risk adenoma and normal 
epithelium to CRC stage A does not translate into equivalent relative risk of CRC, so values had to be 
adjusted through calibration. 
A simple iterative process was chosen which incorporated the following steps: 
1. The model was run for 200 sets of individuals in HSE 2014 population using a starting set of 
relative risks to calculate personalised transitions from normal epithelium to low risk 
adenomas, and normal epithelium to CRC stage A for each individual. Initially this starting 
set was based on the published relative risks described in Table 6 and the default 
individualised genetic relative risks calculated from the Huyghe et al (2019) paper 6. 
2. Following model running, the weighted incidence of CRC in individuals with and without 
each characteristic was calculated and a modelled relative risk of CRC calculated. For genetic 
risk, the modelled relative risk was calculated as the weighted incidence in individuals with a 
Huyghe relative risk of above one divided by the weighted incidence in individuals with a 
Huyghe relative risk of below 1 (i.e. high genetic risk vs low genetic risk). 
3. Modelled relative risk was compared against the target (published) relative risk for each 
characteristic. Multipliers were calculated as target relative risk/modelled relative risk.  
4. Multipliers were applied to the starting set used for the last set of model runs, to create a 
new starting set of relative risks for each characteristic.  
This process was repeated multiple times until values converged. Convergence occurred within 10 
iterations for all relative risks. Lower and upper confidence intervals were estimated to be in 
proportion with target lower and upper confidence intervals for phenotypic risks, and were 
calculated directly for genetic risk from the standard deviation of the population distribution of risk. 
To simplify the calibration process, it was assumed that all risk factors were fixed over an individual’s 
lifetime, for modifiable risk factors taking the original value given in or imputed from the HSE 2014 
(i.e. no changes in BMI, alcohol units or physical activity). Table 6 shows both the published and 
calibrated relative risks. 
Table 6: Published and calibrated relative risks of CRC for phenotypic risk factors included in the 
model. Published RRs taken from Brown et al. (2014) 17 (all risk factors apart from ethnicity, family 
history and genetic risk) from Hippisley-Cox et al (2015)19 (ethnicity), from Lowery et al. (2016) 18 
(family history), and calculated from Huyghe et al (2019) 6 (genetic RRs). 
Risk Factor Description Sex Target (published)  Calibrated  
Mean Lower 
CI 
Upper 
CI 
Mean Lower 
CI 
Upper 
CI 
Smoking Current vs 
Never 
Male 1.22 1.07 1.39 1.38 1.12 1.72 
Female 1.22 1.07 1.39 1.38 1.12 1.72 
Former vs 
Never 
Male 1.14 1.05 1.25 1.19 1.06 1.35 
Female 1.14 1.05 1.25 1.19 1.06 1.35 
Overweight & 
Obesity 
Overweight 
vs Healthy 
Male 1.17 1.12 1.22 1.29 1.20 1.38 
Female 1.07 1.01 1.14 1.11 1.02 1.23 
Obese vs 
Healthy 
Male 1.38 1.32 1.44 1.74 1.62 1.88 
Female 1.17 1.06 1.30 1.33 1.11 1.61 
Alcohol (8g 
per unit) 
Light (<12.5g 
per day) vs 
Never 
Male 1 0.94 1.05 0.85 0.79 0.90 
Female 1 0.94 1.05 0.85 0.79 0.90 
Moderate 
(12.5-50g 
per day) vs 
Never 
Male 1.17 1.09 1.25 1.03 1.02 1.05 
Female 1.17 1.09 1.25 1.03 1.02 1.05 
Heavy (50g+ 
per day) vs 
Never 
Male 1.33 1.14 1.56 1.16 1.07 1.26 
Female 1.33 1.14 1.56 1.16 1.07 1.26 
Male 0.903 0.851 0.952 0.84 0.75 0.92 
Physical 
Activity 
(METS) 
>600 METS 
vs <600 mins 
per week 
Female 0.903 0.851 0.952 0.84 0.75 0.92 
Ethnicity Black vs 
White 
Male 0.73 0.56 0.97 0.57 0.34 0.95 
Female 0.70 0.52 0.96 0.65 0.45 0.95 
South Asian 
vs White 
Male 0.55 0.40 0.76 0.41 0.26 0.67 
Female 0.51 0.34 0.77 0.42 0.25 0.72 
Other vs 
White 
Male 0.64 0.46 0.89 0.43 0.23 0.80 
Female 0.75 0.55 1.04 0.70 0.47 1.04 
Family History 
(first degree 
relative with 
CRC, adjusted 
to remove 
genetic risk) 
Family 
history vs no 
family 
history  
Male 2.003 1.47 2.48 3.05 1.86 4.31 
Female 2.003 1.47 2.48 3.05 1.86 4.31 
Genetic risk 
calculated 
from data in 
Huyghes et al. 
2019 paper 
High genetic 
risk (RR > 1) 
vs low 
genetic risk 
(RR < 1) 
Both 1.071 NA NA 1.730 NA NA 
NA = Not Applicable (constant) 
 
Modelling Individual Cancer Risk for Risk Prediction  
A variety of different risk prediction scores were incorporated into the model to enable screening 
strategies based on risk stratification to be assessed. This included the Ma model for prediction of 
CRC risk based on phenotypic factors only 20, the Jeon model for prediction of CRC risk based on 
genetic factors only 21, and the Dunlop model for prediction of CRC risk based on genetic and 
phenotypic factors 22.  
Genetic risk is fixed, whilst phenotypic risk changes over the course of a person’s life. As a 
consequence of this, genetic risk scores were calculated just once in the model at population setup. 
Calculation of relative risk for the Jeon score was done in a similar way to that for the Huyghe 
genetic risk, using information about allele frequency from UK Biobank 7, and the odds ratio per risk 
allele from the Jeon paper 21. The Jeon score uses information about 57 SNPs. 
The Dunlop model uses a points-based scoring system to calculate absolute risk based on 10 SNPs, 
age, sex and family history, based on Scottish data 22. The genetic component of the risk score was 
calculated just once in the model at population setup, whilst calculation of the final risk score, 
including phenotypic risk, was performed annually within the model to reflect changes in age over 
time. Average risk for each age group was given in the Dunlop paper, so the absolute risk score given 
by the Dunlop model was converted to a relative risk by dividing the score by the age-specific 
absolute risk, and then adjusted to ensure that average risk over the whole weighted population was 
1. 
The Ma model is a Cox proportional hazards model for calculation of 10-year absolute CRC risk, 
which includes coefficients for age, BMI, physical activity, alcohol consumption and smoking status 
20. Alcohol consumption categories differ slightly from those used in the model; occasional 
consumption was assumed to equate to light consumption as defined in Brown et al. (2018) (<87.5g 
per week) 17. Calculation of the Ma risk score was performed annually within the model to reflect 
changes in population characteristics over time, using the following equation: 
10-Year Absolute Risk = (1 – baseline survival function ^ exp(є(ɴ * (value – mean value)))) 
Where value = individual value for each characteristic, mean value = population mean as given in Ma 
paper, ɴ = ɴ coefficient for that characteristic, baseline survival function = 10 year baseline survival 
function. 
Table 7: Ma model for 10-year absolute CRC risk-prediction 20 
Risk Factor Ȳ
Coefficient 
Hazard Ratio 
(Mean) 
Hazard Ratio 
(Lower 95% CI) 
Hazard Ratio 
(Upper 95% CI) 
Age (Year) 0.080 1.08 1.07 1.10 
BMI (kg/m2) 0.047 1.05 1.02 1.08 
Physical Activity (MET hours 
per day) 
-0.019 0.98 0.97 0.99 
Alcohol Consumption: Never -0.163 0.85 0.56 1.28 
Alcohol Consumption: 
Occasional 
0 1 NA NA 
Alcohol Consumption: 
Regular  <300g/week 
0.358 1.43 0.98 2.09 
Alcohol Consumption: 
Regular >=300g/week 
0.659 1.93 1.32 2.83 
Smoking Status: Never 0 1 NA NA 
Smoking Status: Former 0.071 1.07 0.83 1.39 
Smoking Status: Current 0.238 1.27 1.01 1.60 
Baseline survival function at 
10 years 
0.9882 NA NA NA 
 
The Ma risk score is based on a population of Japanese men, in whom the absolute risk of CRC is 
considerably higher than in the UK population (Table 8) 16 20. The absolute risk score given by the Ma 
model was therefore converted to a relative risk by dividing the score by the absolute risk in a 
Japanese male population of the same age as the modelled individuals, and then adjusted to ensure 
that average risk over the whole weighted population was 1. 
An additional genetic plus phenotypic risk score was implemented in the model through combining 
the Ma and Jeon risk scores 20 21. This was achieved by simply multiplying together the individual 
relative risks obtained by each score separately.  
Following calculation of a CRC relative risk using any of the risk scores described above, it was 
necessary to convert this into an age at first FIT screen. The approach used was to base screening 
start age for all individuals on the age at which they were calculated to reach a user-defined 10-year 
absolute risk level, assuming that all risk factors apart from age and sex would remain constant. 
Absolute risk was obtained from CRC incidence rates per 100,000 population by age and sex from 
CRUK 16, and converted to 10-year absolute risk using the following equation.  
10-Year Absolute Risk = 1 - exp(-10 * rate / 100000) 
Screening start age was calculated as the age at which absolute risk was equal to user-defined risk 
divided by the individual relative risk score. 
Table 8: 10-year absolute CRC risk in Japanese and UK populations, from Ma et al (2010) 20 and 
derived from CRUK 16 respectively. 
Age Group Japanese Population UK Population (Male) UK Population (Female) 
40-44 0.5% 0.13% 0.12% 
45-49 0.9% 0.23% 0.21% 
50-54 1.4% 0.47% 0.38% 
55-59 1.9% 0.84% 0.61% 
60-64 2.7% 1.51% 0.91% 
65-69 3.0% 1.98% 1.19% 
Survival and Mortality 
CRC Mortality 
Individuals can either die from CRC or from other causes. Survival following CRC diagnosis is known 
to vary by age, sex, socioeconomic deprivation, diagnostic route, cancer stage, cancer location and 
time since diagnosis, and has also seen significant improvements in recent years, some of which may 
reflect an increase in diagnosis through screening, which has improved survival compared to 
symptomatic diagnosis 23-27. However, detailed and up-to-date information about CRC survival, 
taking all these variables into account, is not currently available for England. Instead, available 
information from a variety of sources was combined to produce an estimate of survival for the first 
ten years following CRC diagnosis by age, sex and stage. It was assumed that anyone surviving for 
ten years post-diagnosis was cured and would have no further risk of death from CRC. 
One and five year net CRC survival data by age group, sex and stage is available from the Office for 
National Statistics (ONS) based on data from adults diagnosed between 2013 and 2017 in England 28 
(Table 9).  
Table 9: Net one and five year survival by age group, sex and stage for 2013-2017 from ONS 28. 
Sex Age 
 
1 Year 5 Years 
Stage 
A 
Stage 
B 
Stage 
C 
Stage 
D 
All  Stage 
A 
Stage 
B 
Stage 
C 
Stage 
D 
All  
Male 15 to 44 99% 98% 94% 60% 87% 98% 86% 70% 19% 66% 
45 to 54 99% 99% 95% 60% 85% 96% 89% 73% 15% 62% 
55 to 64 99% 97% 95% 57% 86% 96% 88% 73% 14% 66% 
65 to 74 98% 95% 92% 48% 82% 94% 85% 69% 13% 63% 
75 to 79 95% 89% 82% 31% 68% 80% 76% 51% 5% 46% 
All ages 97% 93% 90% 44% 78% 90% 82% 64% 10% 57% 
Female 15 to 44 100% 99% 97% 61% 88% 98% 92% 79% 17% 70% 
45 to 54 100% 98% 96% 61% 87% 98% 89% 77% 17% 66% 
55 to 64 99% 98% 96% 55% 86% 96% 90% 77% 15% 67% 
65 to 74 99% 95% 91% 44% 81% 97% 86% 70% 12% 64% 
75 to 79 96% 88% 76% 24% 62% 85% 77% 49% 5% 44% 
All ages 98% 92% 86% 39% 74% 92% 83% 64% 10% 55% 
 
Whilst this data was sufficient to inform one and five year survival, a method was required to 
estimate survival for years two to four and six to ten post diagnosis. Data about net CRC survival for 
every year up to ten years after diagnosis from 2010/11 is available from CRUK 29 (Table 10). This is 
presented by sex, but not by age or stage, and is fairly similar to the ONS values for year one and five 
survival over all ages and stages. Therefore, it was assumed that the ratio between average five-year 
survival and other year survival would remain constant. Ratios of five-year survival to all subsequent 
years were derived using the following equation. 
Ratio(stage, age, year x/year 5) = 1 - ( (1 - Ratio(stage, age, year 5/ year 1)) / (1 - Ratio(year 5/year 1)) * (1 - Ratio(year x/year 5))) 
These ratios were then applied to the five-year survival by age, stage and sex to obtain survival for 
all other years by age, stage and sex (Figure 15). 
Table 10: Net survival up to ten years after diagnosis for 2010/11 from CRUK 29. Note that nine and 
ten-year survival in women is slightly higher than eight-year survival, so it was assumed in the 
calculations above that survival was identical in years eight to ten, to avoid negative mortality. 
Years after Diagnosis Men Women 
0 100.0% 100.0% 
1 77.4% 73.9% 
2 69.5% 66.3% 
3 64.5% 61.9% 
4 61.2% 59.5% 
5 59.2% 58.2% 
6 58.0% 57.5% 
7 57.2% 57.1% 
8 56.6% 57.0% 
9 56.3% 57.1% 
10 56.0% 57.2% 
 
Probability of dying due to CRC was calculated from the survival data as follows: 
CRC_mort(age, sex, stage, year) = 1 – (CRC_surv(age, sex, stage, year) / CRC_surv(age, sex, stage, year-1)) 
It was assumed that the probability of dying from CRC beyond ten years post diagnosis was 0. A 
multiplier was incorporated into the modelling of CRC mortality to enable model users to globally 
increase or decrease CRC mortality over all ages, sexes, stages and years since diagnosis. 
Figure 15: Imputed CRC survival by age, sex and stage.  
 
Some assumptions had to be made around classification of mortality in undiagnosed individuals with 
CRC. In practice, mortality from CRC will only be registered as such if diagnosis of CRC has occurred – 
either prior to death, or following death during a post-mortem. This means that individuals who die 
from CRC that never get diagnosed will be registered as dying from other causes, and therefore the 
death certificate data used in the model will reflect this under-diagnosis. This led to two logical 
alternatives that could be implemented in the model – either individuals who die when undiagnosed 
are assumed to die from other causes, or they die from CRC but are automatically diagnosed with 
CRC within the same model cycle. A combination of these two approaches was chosen, depending 
upon CRC stage, to reflect the available evidence that a small proportion of diagnoses are noted 
through death certificates only 30. For stages A-C, undiagnosed individuals were assumed to have a 
0% probability of dying from CRC in any given model cycle. For stage D, undiagnosed individuals 
were assumed to have the same probability of dying from CRC as those who are in the first year of 
diagnosis. Of those with undiagnosed stage D that died from CRC, a proportion were assumed to be 
diagnosed within the year of death, with the rest remaining undiagnosed. The proportion dying from 
CRC but remaining undiagnosed was obtained through calibration and was assumed to be zero for 
those aged under 75, then to increase linearly with age above 75. 
 
Other Cause Mortality 
All-cause mortality by age and sex was obtained from English life tables for 2016-2018 31. This 
includes mortality from CRC and mortality from other causes. Death registration summary statistics 
for England and Wales (2018) 32 were used to determine the proportion of all registered deaths that 
were due to CRC. It was assumed that CRC deaths included deaths due to ICD code C18: Malignant 
neoplasm of colon and ICD codes C19-21: Malignant neoplasm of rectosigmoid junction, rectum and 
anus. Anal cancer is not included in CRC, but it was not possible to separate this out from rectal 
cancer in death registration data. Other cause mortality was then calculated by subtracting CRC 
mortality from all-cause mortality using the following equation: 
Oth_Cause_Mort(age, sex) = All_Cause_Mort(age, sex) * (1 – (N_CRC_Deaths(age, sex) / N_All_Deaths(age, sex))) 
Screening 
As default the model can simulate the two different screening modalities that are currently used in 
England; Faecal Immunochemical Testing (FIT) and Flexible Sigmoidoscopy (FS). The screening 
pathways modelled reflect the pathways currently used in England; however, specification of 
eligibility criteria is flexible to enable a range of different screening strategies to be easily modelled.  
FIT Screening 
FIT Eligibility 
The modelled FIT screening pathway is shown in Figure 16. Eligible individuals are invited to FIT 
screening. The default eligibility criteria reflect the current eligibility in England and are specified as 
follows: 
x No history of CRC diagnosis 
x Not undergoing surveillance 
x Age 60, 62, 64, 66, 68, 70, 70 or 74. 
Figure 16: FIT screening pathway and follow-up investigations 
 
FIT Uptake 
Response to FIT screening varies depending upon individual characteristics. The English FIT pilot 
results included a multivariate analysis of adequate uptake which provided odds ratios for uptake by 
screening modality (gFOBT or FIT), age group, sex, screening episode, deprivation (IMD quintiles) and 
region 33. This indicates that uptake is lower in males, older age groups, more highly 
socioeconomically deprived groups and in screening non-responders. Model coefficients were 
calculated by taking the log of each odds ratio. Uptake in the reference group (gFOBT, male, age 59-
64, IMD1 [least deprived], first screening round, Midlands and North West Hub) was 53.6% (personal 
communication from Christopher Mathews). This information was used to calculate an intercept for 
the model using the formula: intercept = -LN((1/x)-1) where x = baseline proportion uptake with 
gFOBT. The intercept was then adjusted to represent country-wide FIT screening by adding the 
coefficient for FIT screening and half the coefficient for the Southern Hub region. Odds ratios and 
model coefficients are shown in Table 11.  
Table 11: Odds Ratios from Moss et al (2017) 33 and calculated model coefficients used to predict FIT 
uptake 
Variable Odds Ratio (95% CI) Coefficients (95% CI) 
Intercept NA 0.710 (0.627 to 0.802) 
Age 65-69 0.89 (0.88; 0.9) -0.117 (-0.128 to -0.105) 
Age 70+ 0.79 (0.78; 0.8) -0.119 (-0.121 to -0.118) 
Sex Female 1.15 (1.14; 1.16) 0.140 (0.131 to 0.148) 
Prevalent  non-responder 0.16 (0.156; 0.161) -1.833 (-1.858 to -1.826) 
Incident 6.55 (6.45; 6.54) 1.879 (1.864 to 1.878) 
IMD2 0.93 (0.91; 0.94) -0.073 (-0.094 to -0.062) 
IMD3 0.86 (0.85; 0.88) -0.151 (-0.163 to -0.128) 
IMD4 0.75 (0.73; 0.76) -0.288 (-0.315 to -0.274) 
IMD5 (most deprived) 0.55 (0.54; 0.55) -0.598 (-0.616 to -0.598) 
 
Given that the model will be used to assess the impact of screening at ages below 60, data from the 
Scottish Bowel Screening Programme 2017-18 was used to inform FIT uptake between ages 50 and 
60 34. FIT uptake in Scotland is 66% in people aged 60-64, but only 60% in people aged 55-59 and 
58% in people aged 50-54. This data was converted into log odds coefficients to be used in the 
regression in the same way as the other coefficients. It was assumed that individuals aged under 50 
would have the same uptake as those aged between 50 and 54. 
Table 12: Odds Ratios derived from the Scottish Bowel Screening Programme uptake data34 and 
calculated model coefficients used to predict FIT uptake 
Variable Odds Ratio (95% CI) Coefficients (95% CI) 
Age 50-54 0.694 (0.694; 0.695) -0.365 (-0.366 to -0.364) 
Age 55-59 0.778 (0.777; 0.778) -0.252 (-0.252 to -0.251) 
 
There is also evidence that uptake of screening may be lower in some ethnic minority groups. Whilst 
no evidence about this could be found specifically for FIT screening in England, there was evidence 
from gFOBT screening in England that people of Asian ethnicity have considerably lower uptake, 
even after adjusting for deprivation 35. No evidence could be found to inform uptake in other ethnic 
minority groups. 
Table 13: Odds ratios and calculated model coefficients for uptake of FIT in people of Asian ethnicity 
compared to non-Asian people 35. 
Variable Odds Ratio (95% CI) Coefficients (95% CI) 
Asian ethnicity  0.390 (0.353; 0.434)  -0.941 (-1.041 to -0.834) 
 
In the FIT pilot, individuals that did not send their FIT screening kit back were sent reminder letters. 
Amongst those that did return kits, around 2% required an additional kit to be sent before an 
adequate sample was received. These processes were not explicitly modelled, but were included in 
costings. 
FIT Sensitivity and False Positives 
Sensitivity of the FIT test is likely to depend upon a range of factors including FIT threshold, sex, age, 
screening round and test manufacturer. Published estimates of FIT sensitivity and specificity do exist 
and have been summarised in a meta-analysis by Lee et al (2014) 36. This calculated a mean 
sensitivity of 79% and specificity of 94% for CRC, but the included studies comprised a range of 
different FIT cut-off points, kit manufacturers, number of samples taken and study populations. 
These studies have estimated sensitivity through one of two methods, both of which are flawed. 
Some studies have compared FIT performance against a reference colonoscopy. However; 
colonoscopy sensitivity is not perfect, particularly for low risk adenomas, and depends upon 
colonoscopy quality. Other studies have calculated sensitivity based on the number of interval 
cancers occurring in the two years following the original test. However; this method will miss pre-
existing cancers that take more than two years to manifest symptomatically, or include cancers that 
have developed de novo since screening, which could either over or underestimate sensitivity. 
Furthermore, this method cannot inform sensitivity to adenomas. The differences between the 
population of the included studies and the screening population of England are substantial; many of 
the studies were carried out in Asian populations who are much younger than the English screening 
population, and the underlying CRC prevalence in the study populations is much higher than that 
estimated by the model. Given that the aim of the model was to make decisions around the current 
BCSP (using FIT screening from spring 2019), it was necessary that estimates of sensitivity were 
compatible with detection rates found in large scale UK studies, rather than using direct estimates 
from small, unrepresentative trials. 
The method used to calculate sensitivity was similar to that described previously for the ScHARR 
Bowel Cancer Screening cohort model 37. Following calibration of natural history transition 
probabilities, it was possible to use the model to estimate the underlying prevalence of LR 
adenomas, HR adenomas and CRC in the population for each age and sex, in the absence of 
screening. This was combined with published data about detection rates to estimate sensitivity for 
FIT, as sensitivity is calculated as detection rate divided by prevalence. Note that false positive rate, 
rather than specificity, is used in the model to calculate the risk of false positives in people with 
normal epithelium, so calculations of specificity were not directly required. 
Data about detection rates was available from a range of sources; however, only one English data 
source was available – the UK FIT Pilot 33. Data from individuals screened for the first time (prevalent 
round) in the UK FIT pilot was the most appropriate source to use to inform first round screening 
sensitivities given that it used the same population, test kit and test protocol as are now being used 
in the English BCSP. During the pilot, 3,933 individuals aged 60 were screened using FIT for the first 
time. The UK prevalent round FIT pilot data had some limitations. Firstly, the published data did not 
include information about detection rates for LR adenomas or about false positives. Secondly, all 
individuals were aged 60 at the prevalent screen, so no information about sensitivity at other ages 
could be gathered. Thirdly, the number of individuals diagnosed with CRC as a result of screening 
was low in the prevalent round (only 6 with FIT20), reducing the accuracy of estimates of CRC 
sensitivity. To investigate the accuracy of the sensitivity estimates and to investigate trends by age, 
sex, screening round and FIT threshold, a comparison of FIT pilot detection with data from other 
countries was carried out (see Appendix C for details). A series of steps were then undertaken to 
process the data in order to incorporate additional information from other data sources: 
1. Detection rates for CRC and HR adenoma at five different FIT thresholds were calculated 
from the data for prevalent first time screenees from the UK FIT pilot (Table 14) 33. Note that 
detection rates for CRC are based on very small numbers, and evidence from our 
international comparisons indicated that CRC detection rate was likely to be underestimated 
by UK FIT pilot data (and underestimated in our previous model). 
Table 14: Detection rates from prevalent first time screenees from the UK FIT pilot 33 
 
FIT20 FIT40 FIT100 FIT150 FIT180 
Detection Rate CRC 0.0015 0.0015 0.0008 0.0008 0.0008 
Detection Rate HR Adenoma 0.0150 0.0114 0.0071 0.0053 0.0051 
 
2. An Office for Data Release request was made to the FIT pilot study which enabled 
unpublished data about detection rates for CRC, HR adenomas, LR adenomas and false 
positives to be obtained for the age 59-64 age group (all screenees, N = 11,105). This was 
compared against the prevalent round data and was found to be similar for HR adenomas, 
but higher for CRC detection. The CRC detection rate was therefore re-estimated as a fixed 
proportion of the HR adenoma detection rate for each FIT threshold, to match the 
proportions from the ODR request data (Table 15). LR adenoma detection rates were 
calculated as a proportion of HR adenoma detection rates in the same way. False positive 
rates were estimated by calculating the numbers of individuals with LR adenoma, HR 
adenoma, CRC and therefore false positive results expected in the prevalent round using the 
new detection rates. Confidence intervals for each value were estimated based on the 
numbers of individuals in the prevalent round (not shown). 
Table 15: Estimated detection rates following adjustment using data from all screenees in FIT pilot. 
 
FIT20 FIT40 FIT100 FIT150 FIT180 
Estimated Detection Rate CRC 0.0020 0.0019 0.0017 0.0016 0.0016 
Detection Rate HR Adenoma 0.0150 0.0114 0.0071 0.0053 0.0051 
Estimated Detection Rate LR Adenoma 0.0163 0.0100 0.0048 0.0033 0.0028 
Estimated False Positive Rate 0.0216 0.0112 0.0040 0.0035 0.0017 
 
3. Published data about CRC and HR adenoma detection rates by sex are available from the FIT 
pilot for all screenees by FIT threshold 33. Separate estimates for male and female detection 
rates were calculated by assuming the same ratio male to female for each FIT threshold and 
disease state. Given the lack of published data about LR adenomas, they were assumed to 
follow the same male to female ratio as HR adenomas. The male to female ratio for false 
positives was estimated without taking LR adenomas into account. 
4. Sensitivity at the first screen was then calculated directly using the following formula: 
Sensitivity (disease state, sex, FIT threshold)    =  Detection Rate (disease state, sex, FIT threshold)              
Underlying Prevalence (disease state, sex) 
5. Detection rates by FIT threshold were found previously to follow a power curve distribution 
following the formula y = a*x^b; where a is the intercept, b is a parameter and x is the FIT 
threshold 37. Sensitivity and false positive rates were also found to fit a power curve with the 
same FIT threshold parameter but different intercept from the detection rate curves. Power 
curves were fitted in R and the intercept of those curves obtained in order to enable 
sensitivity and false positive rates to be estimated for any FIT threshold (Table 16 & Figure 
17).  
Table 16: Power curve parameters to calculate sensitivity and false positive rate by FIT threshold, sex 
and underlying disease state, together with calculated sensitivity at a threshold of FIT20 for age 60. 
 
Intercept  
(95% CI] 
FIT_Param  
(95% CI) 
FIT20 Sensitivity  
Male Sensitivity to CRC 0.526 (0.270; 0.867) -0.083 (-0.145; -0.054) 0.410 (0.175; 0.738) 
Male Sensitivity to HR 
Adenoma 
1.071 (1.047; 1.096) -0.487 (-0.591; -0.413) 0.249 (0.184; 0.328) 
Male Sensitivity to LR 
Adenoma 
0.841 (0.706; 1.207) -0.784 (-0.981; -0.654)  0.080 (0.037; 0.170) 
Male False Positive Rate 0.510 (0.361; 0.975) -1.02 (-1.293; -0.847) 0.024 (0.008; 0.077) 
Female Sensitivity to CRC 0.353 (0.176; 0.582 -0.171 (-0.232; -0.142) 0.211 (0.088; 0.380) 
Female Sensitivity to HR 
Adenoma 
1.205 (1.177; 1.233) -0.555 (-0.659; -0.481) 0.229 (0.169; 0.301) 
Female Sensitivity to LR 
Adenoma 
0.630 (0.529; 0.905) -0.852 (-1.05; -0.723) 0.049 (0.023; 0.104) 
Female False Positive Rate 0.538 (0.382; 1.029) -1.082 (-1.335; -0.909) 0.021 (0.007; 0.068) 
 
Figure 17: Curves indicating how FIT sensitivity and proportion of false positives varies by FIT 
threshold in males (green) and females (blue). Fitted power curves are shown by the dotted lines. 
 
 
6. The next step was to incorporate age and screening round into the sensitivity and false 
positive estimates. Our review of international data identified a Veneto study based on 
screening of over 123,000 individuals in Italy as the best source of data about these effects 
38. This study estimated the independent effects of age and screening round on detection 
rates using multivariable analysis. We also calculated similar age effects using an 
independent data source from the first round of the Dutch screening programme 39, and 
calculated an equivalent age effect for false positive rate, not included in the Veneto study. 
The Veneto data indicates that detection rates increase exponentially with age; however, 
prevalence also increases by age, so the age effect multipliers were converted into 
sensitivities using modelled prevalence. This analysis indicated that age had no significant 
impact on sensitivity of FIT to CRC, but that it did increase sensitivity to HR and LR 
adenomas. To account for changing prevalence by age, the false positive rate was first 
converted into specificity for two different ages using the following equation: 
Specificity (age, sex)  =  (1 - False Positive Rate (age))              
Underlying Prevalence (age, sex) 
The false positive rates were then estimated assuming identical underlying prevalence and 
the age effect multipliers recalculated (Table 17). 
Table 17: Age effect multipliers (age parameters) applied exponentially per year of age over 60 
 
For detection rates from 
Veneto study 38  prevalence 
not considered (95% CI) 
Calculated for sensitivity taking 
prevalence by sex into account (95% CI) 
Male Female 
CRC 
Detection/Sensitivity 
1.077 (1.062; 1.093) 0.999 (0.985; 1.014) 1.008 (0.993; 1.023) 
HR Adenoma 
Detection/Sensitivity 
1.049 (1.042; 1.055) 1.027 (1.021; 1.034) 1.014 (1.007; 1.020) 
LR Adenoma 
Detection/Sensitivity 
1.041 (1.032; 1.049) 1.034 (1.026; 1.043) 1.026 (1.018; 1.035) 
False Positive Rate 1.048 ( 1.045; 1.051) 1.056 (1.040; 1.071) 1.056 (1.040; 1.072) 
 
7. A reduction in detection rates and false positives is seen in subsequent screening rounds, 
but prevalence is lower too, due to the impact of the first screen 38. The effect of a second 
screening round on sensitivity and false positive rates was calculated in a similar way to the 
age parameters, taking into account the underlying prevalence two years after a round of 
screening carried out using the screening sensitivities calculated in steps 1-6 above. This 
indicates that sensitivity does diminish in subsequent screening rounds. Once calculated and 
included in the modelling, the additional impact of a third screening round could also be 
calculated, although this was found to only be significant for CRC sensitivity and false 
positives. Note that these screening round multipliers have been calculated for a screening 
interval of two years; however, in the model we assume that they hold for subsequent 
screening rounds no matter how large the interval between an individual’s previous and 
subsequent screen. 
Table 18: Screening round multipliers (compared to previous round) 
 
Round 2 (95% CI) Round 3 (95% CI) 
Male Female Male Female 
Sensitivity to CRC 0.991  
(0.825; 1.177) 
1.016  
(0.847; 1.207) 
0.845  
(0.676; 1.081) 
0.863  
(0.690; 1.104) 
Sensitivity to HR 
Adenoma 
0.827  
(0.763; 0.909) 
0.829  
(0.764; 0.910) 
NS NS 
Sensitivity to LR 
Adenoma 
0.823  
(0736; 0.909) 
0.801  
(0.717; 0.885) 
NS NS 
False Positive 
Rate 
0.604  
(0.595; 0.613) 
0.634  
(0.624; 0.644) 
0.517  
(0.499; 0.526) 
0.550  
(0.531; 0.560) 
 
The estimated parameters enabled a personalised probability of a positive result at FIT screening to 
be calculated for each modelled individual based upon their age, sex, underlying disease state, 
screening history and selected FIT threshold, using the following equations: 
Prevalent Screening Round 
Probability(D, S, Age, FIT_Thresh) = Intercept(D, S) * (FIT_Thresh ^ Param(D, S)) * (Age_Param ^ (Age – 60)) 
Subsequent Screening Rounds 
Probability_Scr2(D, S, Age, FIT_Thresh)  = Probability_Scr1(D, S, Age, FIT_Thresh)  * Round2_Effect 
Probability_Scr3+(D, S, Age, FIT_Thresh)  = Probability_Scr2(D, S, Age, FIT_Thresh)  * Round3_Effect 
where D = Disease State and S = Sex. 
  
FS Screening 
FS Eligibility 
The modelled FS screening pathway is shown in Figure 18. All eligible individuals are invited to FS 
screening. The default eligibility criteria reflect the current eligibility in England and are specified as 
follows: 
x No history of CRC diagnosis 
x Not undergoing surveillance 
x Age 55. 
Figure 18: FS screening pathway and follow-up investigations 
 
FS Uptake 
FS uptake in the BCSP is currently 44% 40; however, it varies depending upon individual 
characteristics. A multivariate analysis of BCSP data by McGregor et al. (2016) 41 provided odds ratios 
for uptake by sex and socioeconomic deprivation (IMD quintiles). The multivariate analysis also 
included area-based ethnic diversity quintiles, locality and type of appointment offered as variables. 
However, with the exception of some of the local areas, these were not significant predictors and in 
any case could not be included in the model as they did not relate to the HSE 2014 baseline 
characteristics. Whilst the sample used for analysis is less up-to-date than current estimates, the 
overall uptake was very similar (43% rather than 44%) suggesting that uptake has not changed 
considerably over time. Model coefficients were calculated by taking the log of each odds ratio. 
Uptake in the reference group (female & IMD5 [most deprived]) was unknown, but was estimated 
from the reported data as 31.5%, assuming that the proportion female in the IMD5 group was the 
same as the proportion female in the total population. This information was used to calculate an 
intercept for the model using the formula: intercept = -LN((1/x)-1) where x = reference group uptake 
with FS. Odds ratios and model coefficients are shown in Table 19.  
Table 19: Odds Ratios from McGregor et al (2016) 41 and calculated model coefficients used to predict 
FS uptake 
Variable Odds Ratio (95% CI) Coefficients (95% CI) 
Intercept NA -0.778 (-0.870 to -0.689) 
Sex Male 1.15 (1.09; 1.21) 0.139 (0.083 to 0.194) 
IMD1 (least deprived) 2.05 (1.85; 2.27) 0.716 (0.614 to 0.818) 
IMD2 1.77 (1.60; 1.95) 0.569 (0.471 to 0.666) 
IMD3 1.44 (1.32; 1.58) 0.367 (0.274 to 0.460) 
IMD4 1.20 (1.09; 1.31) 0.181 (0.090 to 0.272) 
 
Currently, FS screening in the BCSP only relates to a single age group: age 55; however, uptake is also 
likely to vary by age. The UK Flexible Sigmoidoscopy Screening Trial (UKFSST) trialled FS in a range of 
ages from 55 to 65 42. Uptake was much higher than is currently found in the BCSP (73% at age 55), 
but tended to be slightly lower in older ages, corresponding to -2.7% per year of age above 55 
(Figure 19). Normalising this to the average 44% uptake in the BCSP resulted in an average reduction 
of 0.163% (95% CI 0.108% to 0.223%) per year of age above 55 (Table 20). It was assumed that 
uptake would reduce linearly for ages above 65 and increase linearly for ages under 55. 
Figure 19: Trends in FS uptake by age from the UKFSST 42 
 
Table 20: Odds ratios (normalised to BCSP mean uptake) and calculated model coefficients for uptake 
of FS in people per year of age greater than 55. 
Variable Odds Ratio (95% CI) Coefficients (95% CI) 
Asian ethnicity  0.994 (0.994; 0.994)  -0.0056 (-0.0055 to -0.0057) 
 
A study based on the UKFSST was also used to inform uptake by ethnicity, which was found to be 
considerably lower in people of Asian ethnicity than those of from either white or black ethnic 
groups 43. Again, results were normalised to BCSP uptake and model coefficients were calculated as 
log odds ratios. 
Table 21: Odds ratios (normalised to BCSP mean uptake) and calculated model coefficients for uptake 
of FS in people of Asian ethnicity compared to white people. 
Variable Odds Ratio (95% CI) Coefficients (95% CI) 
Asian ethnicity  0.681 (0.510; 0.876)  -0.385 (-0.673 to -0.132) 
 
Sensitivity and False Positives 
It is assumed that specificity of FS is 100% due to the nature of the test and therefore that the 
probability of false positives is zero. Sensitivity of FS to CRC, HR adenomas and LR adenomas is likely 
to vary by personal characteristics including age, sex and whether previously screened. Whilst 
published estimates of FS sensitivity using colonoscopy as a reference do exist, there are problems 
with these similar to those described above for FIT screening. Furthermore, given that individual 
adenomas are not modelled, the estimates of sensitivity need to include the overall outcomes of the 
test including detection of disease at any follow-up investigations that occur as a result of a positive 
FS result. It was therefore particularly important that sensitivity estimates were derived from UK 
large-scale screening data. A similar process to that described for estimating FIT sensitivity, based on 
dividing detection rates by modelled prevalence, was therefore carried out to estimate FS sensitivity. 
Data about detection rates of CRC and HR adenoma following FS in over 34,000 people are available 
from the BCSP 40. Unfortunately, the data about LR adenoma detection is incomplete. Separate data 
is available for men and women; however, as FS is only given at age 55, no information can be 
obtained through the BCSP about detection at other ages. Data about detection rates of all three 
disease states is available from the UKFSST for a total of over 40,000 patients aged 55 to 65, and by 
sex 42. For both these data sources, no patients have been previously screened, so no information is 
available about detection rates following previous screening. A graph of detection rates by age and 
sex is shown in Figure 20 to Figure 22. This indicates that slightly lower detection rates were found 
for CRC and HR adenomas in 55 year olds in the BCSP compared with the UKFSST. There is a lot of 
uncertainty around the CRC detection results due to small numbers (only about 10 for each age 
group in the UKFSST, and 58 in the BCSP). It was decided to use the BCSP data where available due 
to the larger numbers and the representation of a screening rather than a trial population, and use 
UKFSST results to inform the age trend and the LR adenoma results (for the latter it was assumed 
that there was no reduction in detection rate compared to the UKFSST). It is unclear whether the 
trends in detection rates by age are linear or exponential; however, given that an exponential trend 
seemed to fit FIT detection by age, this curve format was also used for FS detection by age. 
Figure 20: Trends in CRC detection rates following FS screening by age based on data from the 
UKFSST 42 
 
Figure 21: Trends in high risk adenoma detection rates following FS screening by age based on data 
from the UKFSST 42 
 
Figure 22: Trends in low risk adenoma detection rates following FS screening by age based on data 
from the UKFSST 42 
 
Sensitivity estimates were first performed for age 55, then the impact of the age effect on sensitivity 
calculated through comparison with sensitivity estimated aged 60. The parameters enabled a 
personalised probability of a positive result at FS screening to be calculated for each modelled 
individual based upon their age, sex and underlying disease state using the following equation: 
Probability(Disease State, Sex, Age) = Sensitivity_Age55(Disease State, Sex) * (Age_Param ^ (Age – 55)) 
Table 22: Parameters used to calculate FS sensitivity by age, sex and disease state 
 
Sensitivity_ Age55 (95% CI) Age_Param (95% CI) 
Male Sensitivity to CRC 0.438 (0.295; 0.581) 1.034 (0.969; 1.140) 
Male Sensitivity to HR Adenoma 0.486 (0.447; 0.526) 0.988 (0.972; 1.005) 
Male Sensitivity to LR Adenoma 0.394 (0.369; 0.418) 0.999 (0.988; 1.011) 
Female Sensitivity to CRC 0.366 (0.213; 0.519) 0.947 (0.927; 0.969) 
Female Sensitivity to HR Adenoma 0.380 (0.329; 0.431) 0.947 (0.927; 0.969) 
Female Sensitivity to LR Adenoma 0.321 (0.294; 0.348) 0.978 (0.964; 0.994) 
  
Further Investigation with Colonoscopy and CTC 
All individuals testing positive with FIT or FS go on to be invited to further investigations. It is 
assumed that criteria for further investigation would be the same for FIT as currently for gFOBT in 
the BCSP. For FS, the data from the BCSP is unclear about the eligibility criteria for further 
investigation; in the UKFSST no-one with LR adenoma was investigated further 42 whilst a proportion 
of those with LR adenoma or other abnormalities also appear to be invited in the BCSP and it is 
unclear why. The total number of people requiring further investigation in the BCSP 2014/15 was 
1,544 40; slightly higher than the sum total found to have CRC, HR, or LR adenomas (1,377), and 
therefore it was assumed in the model that all individuals found to have adenomas of any risk level 
would get further investigation.  
CTC Referral 
It is assumed in the model that all FS positives are suitable for colonoscopy, whereas a proportion of 
FIT positives are not suitable and are instead referred to CTC. The proportion referred to CTC 
through the BCSP increases with age as shown in (Table 23) 40. It was assumed that the rate of 
referral for patients aged under 60 would be the same as for the 60-61 age group, whilst for patients 
aged over 74 it would be the same as for the 72-74 age group. 
Table 23: The proportion of patients referred to CTC rather than colonoscopy after a FIT positive 
result, from BCSP data (2014/15) 40 
Age Group Proportion Referred to CTC (95% CI) 
Age 60-61 3.2% (2.8% to 3.5%) 
Age 62-63 3.7% (3.3% to 4.1%) 
Age 64-65 4.5% (4.1% to 4.9%) 
Age 66-67 4.4% (4.0% to 4.8%) 
Age 68-69 4.7% (4.3% to 5.2%) 
Age 70-71 5.3% (4.8% to 5.9%) 
Age 72-74 6.1% (5.5% to 6.7%) 
 
Uptake 
Data about uptake rates for CTC and colonoscopy following either FIT or FS were obtained from a 
variety of sources. The only UK source of uptake data in FIT positives comes from the UK FIT pilot 33. 
This reported that overall uptake of adequate further investigations (CTC plus colonoscopy) was 
85.7% in FIT positives compared with 85.0% in gFOBT positives. Given the similarity between overall 
uptake in gFOBT and FIT positives, it was therefore thought reasonable to use BCSP data to inform 
uptake rather than FIT pilot data, given that BCSP data is based on larger numbers and reports 
uptake by age, sex, screening round and modality (CTC vs colonoscopy). 
BCSP data from over 200,000 gFOBT positive 2011 to 2015 was used to inform uptake of 
colonoscopy following FIT 33. Similar to FIT pilot estimates, overall uptake was 85%, but the data also 
indicated that uptake varies by age, sex and screening round (Figure 23). Uptake tends to be lower in 
older people, and is considerably lower in the prevalent (first) screening round than in incident 
(subsequent) screening rounds. There is also a significant difference between the sexes for the 
prevalent round, with males taking up colonoscopy more than females; in incident screening rounds 
there is no significant difference between male and female uptake.  
Figure 23: Colonoscopy uptake in FIT positive patients by age, sex and screening round from BCSP 
data 33 
 
Whilst this BCSP data excerpt did not include information about other personal characteristics, there 
is some evidence that colonoscopy uptake in the BCSP varies by deprivation and ethnicity. A study by 
Morris et al (2012) 44 of 24,000 gFOBT positive individuals within the BCSP included a multivariate 
analysis which found that there was significantly lower uptake of colonoscopy in the most deprived 
quintile of the population. However; this trend did not appear to continue in less deprived quintiles. 
Other independent variables included in the model were age and sex (grouped into under and over 
65 for each sex), percentage of the population who were non-white, population density and self-
assessed health. The only other significant variables were proportion non-white and the age over 65 
* female variable. However, the fact that three of the variables could not be incorporated into 
MiMic-Bowel (as they were based on populations rather than individuals), and the low significance 
of most of the variables (probably due to the relatively low sample size), meant that the BCSP data 
was preferred for use in the model.  
To calculate model coefficients for colonoscopy uptake in FIT positives from the BCSP data, linear 
trend lines were fitted to each curve in Excel and intercept and slope calculated. The coefficients 
used to predict colonoscopy uptake are shown in Table 24. 
Table 24: Calculated model coefficients used to predict colonoscopy uptake in FIT positives 
Variable Coefficients (95% CI) 
Intercept 1.169 (1.167 to 1.171) 
Prevalent Screen 0.099 (0.071 to 0.128) 
Age -0.00453 (-0.00463 to -0.00449 
Age * Prevalent Screen -0.00227 (-0.00277 to -0.00171) 
Female Sex * Prevalent Screen 0.056 ( 0.049 to 0.062) 
Age * Female Sex * Prevalent Screen -0.0012 (-0.0014 to -0.0011) 
 
CTC usage in the BCSP was reported in a publication by Plumb et al. (2013) 45, which indicated that 
99.2% of those referred to CTC took it up. No information was provided about differences by age, 
gender or screening round, so a fixed uptake rate was used for all individuals. 
BCSP data was not used to inform uptake of follow-up colonoscopy in FS positives, as the number of 
colonoscopies attended was not recorded in this excerpt. Instead, information from the UKFSST was 
used, which indicated that 96.25% of FS positives referred to colonoscopy took it up 42. No 
information about differences in colonoscopy uptake by personal characteristics were reported. The 
much higher uptake rate compared with gFOBT positives is likely to be due to colonoscopy being a 
similar process to FS and patients having already been identified to have abnormality and therefore 
being more motivated to follow it up further. However, it cannot be excluded that this could be an 
overestimate of actual uptake in the BCSP, given the trial conditions and the slightly different 
eligibility criteria for further investigation used. 
Inadequates 
Not all further investigations lead to an adequate result. It was assumed that 7% of colonoscopies 
had to be repeated (taken from NHS BCSP data 40), and that a further investigation (assumed to be a 
single colonoscopy) was required in 35% of CTC patients 45. No evidence was found to inform 
differences in inadequacy rates by personal characteristics. 
 Sensitivity and Specificity 
It was assumed that colonoscopy specificity for adenomas and CRC is 1. Colonoscopy sensitivity 
however is not perfect. Sensitivity of colonoscopy to CRC was estimated from a population-based 
study which used an interval cancer approach to determine the underlying true incidence of CRC, 
assuming that sojourn time was three years 46. Estimated sensitivity to CRC was 96.6%, which was 
used directly in the model. There are inaccuracies with using the interval cancer method, which may 
underestimate or overestimate sensitivity depending upon the accuracy of estimated sojourn time, 
local detection rates and the rate of de novo development of cancer within the interval period. It is 
also possible that this is an underestimate of sensitivity in the BCSP, as colonoscopy quality is known 
to be particularly high in England due to the long and well-regulated training procedure and has also 
improved over time. However, this was the best data available for CRC sensitivity. No evidence was 
found to inform differences in sensitivity by personal characteristics. 
A 2006 meta-analysis investigated colonoscopy sensitivity for adenomas, measured by tandem 
same-day colonoscopy 13.  This incorporated data from six studies with 465 patients in total. 
Estimated miss rates were 2.1% for polyps larger than 1cm in diameter and 23.5% for polyps under 
1cm in diameter. This data was used in the model to calculate sensitivity (1 – miss rate) for LR 
adenomas (Table 25). HR adenomas are defined both through size and number of lesions, and the 
calculated value for sensitivity of 97.9% based on adenoma size alone is actually higher than that 
used in the model for CRC sensitivity, so was not thought to be valid for representing HR adenoma 
sensitivity in the model. Instead, an alternative estimate was found from a 2013 study comparing 
the diagnostic accuracy of CTC and colonoscopy14. Colonoscopy sensitivity was estimated at 92.5% 
for HR adenomas based on the proportion of adenomas that were not detected with initial 
colonoscopy but were found through CTC and later confirmed through a second colonoscopy where 
the colonoscopist was able to view the CTC images. 
Sensitivity of CTC to CRC and HR adenomas was calculated from the SIGGAR1 study which included a 
multicentre, randomised trial comparing CTC with colonoscopy in patients with symptoms 
suggestive of CRC 47. It was reported that the relative risk for detection of CRC using CTC rather than 
colonoscopy was 0.98, whilst the relative risk for detection of HR adenomas using CTC was 0.82, 
although neither of these two values were significant. In the absence of further data it was assumed 
that the relative risk of detection of low risk adenomas was the same as that of high risk adenomas. 
These relative risks were multiplied by colonoscopy sensitivity for each disease type to obtain values 
for sensitivity of CTC. Sensitivity estimates used in the model are shown in Table 25. CTC specificity 
came from a separate study 
A systematic review of the effectiveness, diagnostic accuracy and harms of CRC screening was 
recently carried out to inform the US Preventive Services Task Force 48. The review included seven 
studies, none from the UK, which estimated the sensitivity and specificity of CTC screening. The 
weighted mean specificity was calculated as 88% for adenomas ш 6mm, or 91% for adenomas ш 
10mm. CTC specificity in the model was assumed to be 88% for all disease types. 
Table 25: Values used in the model for sensitivity and specificity of colonoscopy and CTC  
Parameter Value (95% CI) 
Colonoscopy Sensitivity to CRC 0.966 (0.962 to 0.969) 
Colonoscopy Sensitivity to HR adenoma 0.925 (0.894 to 0.952) 
Colonoscopy Sensitivity to LR adenoma 0.765 (0.733 to 0.796) 
Colonoscopy Specificity 1 
CTC Sensitivity to CRC 0.946 (0.606 to 1.472) 
CTC Sensitivity to HR adenoma 0.803 (0.490 to 1.277) 
CTC Sensitivity to LR adenoma 0.627 (0.381 to 1.018) 
CTC Specificity 0.881 (0.873 to 0.889) 
 
  
Endoscopy Complications 
The model includes a small risk of complications associated with colonoscopy, FS and CTC; including 
perforation, major bleed and death. Given the very small numbers involved, a single estimate for the 
probability of each harm was applied to all individuals in the model. Incidence of hospitalisation for 
bleeding and perforation following FS with or without polypectomy were taken from the UKFSST 42. 
In total, 12 patients suffered a major bleed out of the 40,621 who underwent FS. No individuals 
undergoing FS without polypectomy suffered perforation whereas only one individual out of 9,494 
patients undergoing polypectomy suffered perforation.  
The rate of perforation for colonoscopy was taken from a more recent study of 130,831 patients 
undergoing colonoscopy in the BCSP 49. This reported a colonoscopy perforation rate of 0.031% 
without polypectomy, and 0.091% with polypectomy, with an average of 2.3 polypectomies per 
patient. The rate of bleeding requiring transfusion (represented in the model as hospitalisation) was 
0.04%. Gatto et al (2003) 50 report that the incidence of death subsequent to a perforation within 14 
days of a procedure was 4 out of 77 colonoscopic perforations (5.2%) and 2 out of 31 sigmoidoscopic 
perforations (6.5%). This study refers to a Medicare population, so the cases may be older and in 
worse health than the English screening population; however, no alternative source was identified.  
Risk of perforation following CTC is even lower than for colonoscopy. A rate of 0.02% was assumed, 
in line with results from a systematic review and meta-analysis of the data 51. No individuals died 
following perforation in any of the included studies, so mortality rate following CTC was assumed to 
be 0%. Endoscopy complications are summarised in Table 26. 
Table 26: Probability of endoscopy harms 
Parameter Value (95% CI) 
FS with polypectomy probability of perforation 0.000105 (0.000003 to 0.00039) 
FS without polypectomy probability of perforation  0 
FS probability of hospitalisation for bleeding 0.000295 (0.00015 to 0.00048) 
FS probability of death following perforation 0.0645 (0.0818 to 0.1722) 
Colonoscopy with polypectomy probability of perforation 0.00091 (0.00061 to 0.00128) 
Colonoscopy without polypectomy probability of perforation  0.00031 (0.00014 to 0.00054) 
Colonoscopy probability of hospitalisation for bleeding 0.0004 (0.0003 to 0.00052) 
Colonoscopy probability of death following perforation 0.0519 (0.0145 to 0.1111) 
CTC probability of perforation 0.0002 (0.00007 to 0.00039) 
CTC probability of death following perforation 0 
Surveillance 
The default surveillance pathway in the model follows current NHS BCSP guidelines (Figure 24) 1. The 
model natural history includes only two adenoma health states; low risk and high risk. All individuals 
detected with high risk adenomas are eligible for surveillance; however, these high risk individuals 
are first divided further into intermediate risk and high risk categories. Intermediate risk is defined 
as 3-4 small adenomas or one adenoma of at least 1cm in diameter, whereas high risk is defined as 
either five or more small adenomas, or three or more adenomas of which one is at least 1cm in 
diameter. Those at high risk are eligible for surveillance after one year, whilst those at intermediate 
risk are eligible for surveillance after three years. As the model natural history does not explicitly 
model these as two separate health states, a different method was required to determine which 
individuals would be assigned to high risk and which to intermediate risk adenoma categories.  
Figure 24: Surveillance pathway recommended by NHS BCSP guidelines and replicated in the model 
 
No data was available to inform the proportions of high risk versus intermediate risk detected after 
FIT screening; however, the NHS BCSP records this by age and sex after gFOBT screening 40. The 
proportion of high risk adenomas found (compared with all high and intermediate risk adenomas) 
was plotted by age for males and females separately using data from 44,000 individuals screened 
between 2011 and 2015 (Figure 25). This indicated that male sex and age are both predictors for 
high-risk adenomas. Screening round did not appear to be a predictor for the proportion high risk 
(not shown). The age trend appeared to be reasonably linear, enabling estimation of regression 
coefficients for calculating individualised probabilities of having a high risk adenoma (Table 27). 
Figure 25: Plot showing the proportion of individuals with high risk (rather than intermediate risk) 
adenomas by age and sex, following gFOBT screening in the BCSP, 2001 to 2015 40 
 
Table 27: Regression coefficients used in the model to predict the probability that an individual has a 
high risk adenoma rather than an intermediate risk adenoma following detection through screening. 
Variable Mean Lower 95% CI Upper 95% CI 
Intercept -0.0458 -0.0588 -0.0328 
Male Sex -0.0463 -0.055 -0.0376 
Age 0.0058 0.0057 0.0059 
Age*Male Sex 0.0024 0.0023 0.0024 
 
Individuals who are invited to surveillance colonoscopy may or may not attend. Uptake of 
surveillance colonoscopy was assumed to be 82.5% in line with data from the BCSP 40. In line with 
the BCSP guidelines, individuals in the model who do not attend are invited back for another 
surveillance colonoscopy after the interval relevant to their risk status has passed (i.e. after a further 
three years if they were previously classified as intermediate risk). Individuals found to have high risk 
adenomas at surveillance will undergo polypectomy and then be reinvited after one year. Individuals 
found to have low or intermediate risk findings will undergo polypectomy and then be reinvited 
after three years. Individuals who do not have any adenomas upon surveillance will be reinvited 
after three years; however, if they were originally high risk and then have three consecutive clear 
colonoscopies, or were originally medium risk and then have two consecutive clear colonoscopies 
they are assumed to be very low risk and return to routine screening. Any modelled individual who is 
diagnosed with cancer during surveillance is removed from the screening and surveillance pathway 
and instead follows a disease pathway which includes treatment costs, utility reductions and 
reduced survival compared to the general population. 
Whilst it is known from a study by Bressler et al (2007) that not all adenomas are cleared from the 
bowel upon polypectomy (particularly low risk adenomas) 46, the current model structure 
incorporating only a limited number of health states, rather than individual adenomas, does not 
enable this to be represented. Instead, the Bressler data is used to inform colonoscopy sensitivity 
(i.e. whether or not adenomas are detected), and then it is assumed that polypectomy that takes 
place during screening and surveillance returns all detected individuals back to the normal 
epithelium health state. This is likely to mean that the people undergoing surveillance in the model 
are healthier than in practice, whilst more unhealthy people are returned to the screening pool, 
although it is unclear what impact this would have on model comparisons of different screening 
strategies. Future versions of the model will simulate individual adenomas, enabling colonoscopy 
sensitivity estimates to be applied to each individual adenoma and allowing incomplete adenoma 
clearance upon polypectomy to be simulated. This will be essential for accurate comparison of 
different surveillance strategies. 
Surveillance data from the BCSP indicates that individuals who are undergoing surveillance have a 
much higher risk of developing CRC and adenomas than individuals in the general population 
(personal communication from Stuart Bonnington). It is thought that this is partly due to incomplete 
clearance of adenomas from the bowel during polypectomy (as discussed above), and partly due to 
surveilled individuals being at higher risk of adenoma and CRC development than individuals in the 
general population. However, it was decided that this data should not be used to adjust the natural 
history transition probabilities in people undergoing surveillance, as this could result in surveillance 
inadvertently increasing cancer risk in the model, whereas in reality surveillance should reduce risk. 
This was particularly important given that one of the objectives of MiMiC-Bowel was to enable 
evaluation of different surveillance strategies. If natural variation in cancer risk is accurately 
represented in the model, then individuals who are at high risk due to environmental and genetic 
factors will be those most likely to be picked up with adenomas during screening and therefore to 
undergo surveillance. This should mean that those undergoing surveillance will naturally transition 
faster to adenomas and cancers than individuals in the general screening population.  
  
Utilities 
Utility decrements due to age were calculated as described in the Modelling Changes in Phenotypic 
Characteristics by Age section, and are shown in Table 28. 
A recent review and meta-analysis of CRC utilities by Djalalov et al (2014) was used to estimate 
utility multipliers for CRC 52. The meta-analysis included a linear mixed-effects model for utilities that 
took into account differences in utility measurements by cancer site, stage, time since surgery, 
measurement instrument and method of administration. The reference case was chosen for cancer 
site (colorectal cancer) and method of administration (interviewer), whilst EQ-5D was chosen as the 
measurement instrument. The model indicated that individuals with stage D cancer would have a 
0.19 lower utility than individuals with stage A-C cancer. The model also indicated that utility 
increased after surgery, with values given for before surgery, three months after surgery, one year 
after surgery and more than one year after surgery. This meant that it was possible to estimate 
utilities in the first year after diagnosis (which would likely include treatment with surgery), and for 
subsequent years. The three months after surgery values were chosen to represent the first year 
after surgery, and the more than one year after surgery values were chosen to represent subsequent 
years.  
The values described above are absolute utilities rather than multipliers or decrements. However, no 
average age is given against which to compare values from the general population. An analysis from 
Ara & Brazier (2011) indicates that the average utility of people with a history of cancer is 14% lower 
than that for the general population or for people without a cancer history, and that this doesn’t 
change significantly with age 5. Given that the utility value estimated in the Djalalov model for mixed 
stages, more than one year after surgery is 0.86 52, this implies that it would be reasonable to use 
the Djalalov values as utility multipliers rather than as absolute utilities (which would overestimate 
health related quality of life in cancer). The utility multipliers used in the model by stage and year 
since diagnosis are presented in Table 28. 
There may be a small utility decrement associated with undergoing a screening test; however, such a 
decrement is likely to only last a short period of time. There is no data available for utility values 
during a screening test, so no utility decrement due to screening test was included within the 
modelling. 
Screening harms are associated with transient reductions in utility. It was not possible to find utility 
decrements relating specifically to screening adverse events. As an alternative, utility decrements for 
bleeding were estimated by assuming they would be similar to a major gastrointestinal bleed and 
used the value from Dorian et al. (2014) of 0.1511 for two weeks, i.e. a total QALY loss of 0.00581 in 
the year of occurrence 53. Values for perforation were assumed to be the same as for stomach 
ulcer/abdominal hernia/rupture taken from Ara and Brazier (2011) 5. The disutility value was 0.118 
for one month, i.e. total QALY loss of 0.00983 over a year. 
Individual utility values were modelled annually by first applying the total age decrement calculated 
using the baseline age and EQ-5D for each individual, then applying multipliers due to CRC, then 
applying any transient screening harm decrements. Any individual with utility values greater than 1 
had utility adjusted to 1, whilst any individual with utility values lower than -0.594 had utility 
adjusted to -0.594, reflecting the upper and lower bounds of the EQ-5D score. 
Table 28: A summary of utility decrements and multipliers used in the model 
 Utility Change (95% CI) Multiplier or 
Decrement 
Age -0.00432 (-0.00460; -0.00404) Decrement 
CRC Stage A-C Year 1 0.87 (0.67; 1.07) Multiplier 
CRC Stage A-C Subsequent Years 0.92 (0.76; 1.08) Multiplier 
CRC Stage D Year 1 0.68 (0.42; 0.93) Multiplier 
CRC Stage D Subsequent Years 0.73 (0.51; 0.94) Multiplier 
Bowel Perforation -0.00983 (-0.01058; -0.00917) Decrement 
Intestinal Bleed -0.00581 (-0.00883; -0.00279) Decrement 
  
  
Costs 
Screening and Further Investigation Costs 
FIT screening programme costs were taken from the ScHARR bowel cancer screening cohort model, 
which used costings from the Southern screening hub 37. Previously, costs of individual components 
were combined to give for example separate costs for FIT non-compliers, FIT compliers with normal 
results and FIT compliers with positive results. Costs were structured in a slightly different way for 
MiMiC-Bowel to enable each individual to accumulate costs as they travelled along the screening 
pathway, gathering one cost for being invited, and then separately gathering the additional costs of 
complying (e.g. the cost of processing the test kit) and then getting a positive test (e.g. the cost of an 
appointment with a specialised screening practitioner to discuss further investigation) (Table 29).  
For FS screening, costs from the Southern screening hub were used to estimate all screening costs in 
a similar way to that described for FIT screening, apart from the cost of the FS exam itself, which was 
costed using NHS Reference Costs 2017/18 54. Southern Hub screening costs were inflated from 
2008/09 values to 2013/14 values using the Hospital and Community Health Services (HCHS) pay and 
prices index, and then to 2017/18 values using the new Health Services Index 55. 
Table 29: Screening costs taken from Southern Hub Costings 37, inflated to 2017/18 values 
Screening Procedure Components Included in Costing Cost (95% CI) 
FIT Invite FIT kit, invitation letter, reminder letters in non-
responders, helpline costs, postage, packaging, staff 
costs and overheads. 
£7.45  
(£6.71; £8.20) 
Additional Costs of 
FIT Normal Result 
FIT processing, retests (required in 3% of people), 
normal result letter to patient & GP 
£1.09  
(£0.98; £1.19) 
Additional Costs of 
FIT Positive Result 
Additional costs of positive result letter to patient & 
GP. Specialised screening practitioner appointment. 
£10.23  
(£9.21; £11.25) 
FS Invite Invitation letter, bowel preparation kit, reminder 
letters in non-responders, helpline costs, postage, 
packaging, staff costs and overheads. 
£5.82  
(£5.24; £6.40) 
Additional Costs of 
FS Normal Result 
Normal result letter to patient & GP with postage. FS 
procedure NOT included. 
£1.14  
(£1.03; £1.26) 
Additional Costs of 
FS Positive Result 
Positive result letter to patient & GP with postage. 
Specialised screening practitioner appointment. FS 
procedure NOT included. 
£11.37  
(£10.24; £12.51) 
 
Individuals undergoing further investigations (CTC or colonoscopy) or surveillance colonoscopy incur 
further costs relating to these procedures and the harms arising from these procedures. All further 
investigations and screening harms were costed using NHS Reference costs 2017/18 54. Previous 
versions of NHS Reference costs have provided interquartile ranges, allowing calculation of a 
standard error if it is assumed that the interquartile range is distributed symmetrically around the 
mean. However, the 2017/18 version does not include this. Interquartile ranges from NHS Reference 
costs 2016/17 were therefore combined with the mean from NHS Reference costs 2017/18 to 
provide an estimate of interquartile ranges around the new mean that were proportional to the 
2016/17 values. 
No cost was assigned to invitation to further investigations or surveillance. For CTC, all costs were 
assumed to be incurred upon attending CTC and no additional costs were given for a positive result. 
The cost for CTC was estimated from diagnostic imaging CTC costs relating to CTC for more than 
three areas (Table 30). Different costs were incurred for FS and colonoscopy with and without 
polypectomy. Individuals who did not have any adenomas or cancer detected were assumed to have 
a diagnostic FS or colonoscopy (without polypectomy) whereas those diagnosed with adenomas 
were assumed to have therapeutic FS or colonoscopy (with polypectomy). All of these were costed 
as day case procedures. People diagnosed with cancer were also costed as though they had 
therapeutic FS/colonoscopy – whilst these individuals will not have a polyp removed, they will likely 
have some tissue removed for biopsy instead. Cost of biopsy (costed as histopathology and histology 
within direct access pathology services) was assumed to be incurred by all individuals diagnosed 
with cancer and those with adenomas removed. In individuals with cancer, a single biopsy was 
costed, whilst in those with adenomas removed, the cost of biopsy was multiplied by an estimate of 
the average number of adenomas removed during screening, given as 2.3 in a study of the NHS BCSP 
49. Note that this estimate comes from gFOBT screening rather than FIT or FS screening; however, no 
other data informing this could be found.  
Individuals who suffer screening harms are also expected to incur costs of these harms. Perforation 
from CTC, FS or colonoscopy was calculated as a weighted average of the cost of major large 
intestine procedures with CC score of 0 to 3+, 19 years and over. Bleed from FS or colonoscopy was 
calculated as a weighted average of the cost of gastrointestinal bleed without interventions, with 
single intervention and with multiple interventions. All harms were costed as non-elective short-stay 
procedures. 
Table 30: Costs of screening, further investigation and harm taken from NHS Reference Costs 
2017/18 54 
Procedure Description Cost (Interquartile Range) 
Diagnostic FS FS without polypectomy, Day case £402 (£316; £472) 
Therapeutic FS FS with polypectomy, Day case £512 (£420; £595) 
Diagnostic Colonoscopy Colonoscopy without polypectomy, Day 
case 
£525 (£406; £601) 
Therapeutic Colonoscopy Colonoscopy with polypectomy, Day 
case 
£641 (£508; £735) 
Biopsy Histopathology and histology £33 (£12; £38) 
CTC Scan CT scan of more than three areas £139 (£69; £191) 
Bowel Perforation Weighted average of major large 
intestine procedures with CC score 0-3+ 
£1,554 (£472; £2,295) 
Intestinal Bleed Weighted average of gastrointestinal 
bleed without intervention or with 
single or multiple intervention 
£474 (£391; £532) 
 
CRC Treatment Costs 
Cancer treatment costs were taken from a 2016 costing study by Laudicella et al (2016) that used 
population based, patient level data to estimate the costs of treating four different types of cancer, 
including colorectal cancer, in each year following diagnosis in England 56. The study is limited in that 
it groups early stage (Dukes A & B) and later stage (Dukes C & D), and groups individuals aged 18-64 
or 65+, rather than providing data on a wider range of ages. However, it has two advantages. Firstly, 
it reports costs for up to nine years following diagnosis, which enables treatment costs to be 
allocated to the year they are incurred (rather than assuming they are all incurred in the first year 
after diagnosis), and should mean that most costs of relapse are incorporated. Secondly, costs 
include all healthcare costs incurred by individuals and not those specifically incurred through 
colorectal cancer treatment. This has the advantage that healthcare costs indirectly attributed to 
cancer are included (for example extra care required to treat unrelated conditions in individuals with 
cancer), but the disadvantage that completely unrelated healthcare costs that would also be 
incurred in individuals without cancer are also included. The study does not estimate healthcare 
costs in individuals without cancer as comparison, but does estimate healthcare costs for the three 
years prior to cancer diagnosis. This means that cancer-related healthcare costs over the nine years 
following diagnosis could be estimated by subtracting the three-years pre- diagnosis costs from the 
costs for each year post-diagnosis. Costs in the year immediately prior to diagnosis were significantly 
higher than costs two or three years prior to diagnosis suggesting that these might represent the 
costs of diagnosis. These costs were not included in the model to avoid double counting the costs of 
diagnosis through screening and surveillance. The costing study was carried out in 2010, so costs 
were inflated to 2013/14 values using the Hospital and Community Health Services (HCHS) pay and 
prices index, and then to 2017/18 values using the new Health Services Index 55. 
Table 31: CRCrelated healthcare costs from Laudicella et al 2016 56, inflated to 2017/18 values. 
 Age 18-64 Age 65+ 
Stage A-B Stage C-D Stage A-B Stage C-D 
Year One £16,302 £21,051 £15,233 £16,625 
Year Two £3,826 £6,895 £3,508 £5,242 
Year Three £3,175 £4,713 £2,860 £4,047 
Year Four £2,452 £3,850 £2,379 £3,169 
Year Five £2,206 £2,748 £2,414 £2,965 
Year Six £1,509 £2,300 £2,440 £2,816 
Year Seven £1,569 £2,680 £2,217 £1,800 
Year Eight £1,438 £2,055 £2,458 £2,338 
Year Nine £1,239 £1,413 £2,052 £1,818 
 
 
Appendix A: Parameter Table 
No Parameter Name Mean 95% CI Distribution Source 
1 CRC Relative Risk Current Smoker 1.38 1.12 1.72 Lognormal Calibrated based on Brown et al. 2018 17 
  2 CRC Relative Risk Former Smoker 1.19 1.06 1.35 Lognormal 
3 CRC Relative Risk Overweight Males (BMI 25-29.99) 1.29 1.20 1.38 Lognormal 
4 CRC Relative Risk Overweight Females (BMI 25-29.99) 1.11 1.02 1.23 Lognormal 
5 CRC Relative Risk Obese Males (BMI >=30) 1.74 1.62 1.88 Lognormal 
6 CRC Relative Risk Obese Females (BMI >=30) 1.33 1.11 1.61 Lognormal 
7 CRC Relative Risk Light Alcohol Drinker (<12.5g per day) 0.85 0.79 0.90 Lognormal 
8 CRC Relative Risk Moderate Alcohol Drinker (12.5-50g per day) 1.03 1.02 1.05 Lognormal 
9 CRC Relative Risk Heavy Alcohol Drinker (>50g per day) 1.16 1.07 1.26 Lognormal 
10 CRC Relative Risk High Physical Activity (150+ mins per week) 0.84 0.75 0.92 Lognormal 
11 CRC Relative Risk Black Ethnicity Males 0.57 0.34 0.95 Lognormal Calibrated based on Hippisley-Cox et al. 
201519 12 CRC Relative Risk Black Ethnicity Females 0.65 0.45 0.95 Lognormal 
13 CRC Relative Risk Asian Ethnicity Males 0.41 0.26 0.67 Lognormal 
14 CRC Relative Risk Asian Ethnicity Females 0.42 0.25 0.72 Lognormal 
15 CRC Relative Risk Other Ethnicity Males 0.43 0.23 0.80 Lognormal 
16 CRC Relative Risk Other Ethnicity Females 0.70 0.47 1.04 Lognormal 
17 CRC Relative Risk Family History (genetic risk subtracted) 3.05 1.86 4.31 Lognormal Calibrated based on Lowery et al. 2016 18 
18 Multiplier used for genetic risk 1.73 NA NA Constant Model calibration 
19 Coefficients for proportion with family history: Intercept -0.073 -0.08 -0.06 Normal Calculated from UK Biobank data 7 
 20 Coefficients for proportion with family history: Age 0.003 0.0032 0.0035 Normal 
21 Transition probability: Norm to LR Adenoma Age 35 Male 2.01E-03 NA NA Correlated set Model calibration 
22 Transition probability: Norm to LR Adenoma Age 45 Male 2.68E-02 NA NA Correlated set Model calibration 
23 Transition probability: Norm to LR Adenoma Age 55 Male 1.49E-02 NA NA Correlated set Model calibration 
24 Transition probability: Norm to LR Adenoma Age 65 Male 8.17E-03 NA NA Correlated set Model calibration 
25 Transition probability: Norm to LR Adenoma Age 75 Male 4.36E-03 NA NA Correlated set Model calibration 
26 Transition probability: Norm to LR Adenoma Age 85 Male 3.15E-03 NA NA Correlated set Model calibration 
27 Transition probability: Norm to LR Adenoma Age 35 Female 1.15E-03 NA NA Correlated set Model calibration 
28 Transition probability: Norm to LR Adenoma Age 45 Female 1.62E-02 NA NA Correlated set Model calibration 
29 Transition probability: Norm to LR Adenoma Age 55 Female 1.15E-02 NA NA Correlated set Model calibration 
30 Transition probability: Norm to LR Adenoma Age 65 Female 8.28E-03 NA NA Correlated set Model calibration 
31 Transition probability: Norm to LR Adenoma Age 75 Female 4.01E-03 NA NA Correlated set Model calibration 
32 Transition probability: Norm to LR Adenoma Age 85 Female 3.05E-03 NA NA Correlated set Model calibration 
33 Transition probability: LR to HR Adenoma Age 35 Male 2.82E-02 NA NA Correlated set Model calibration 
34 Transition probability: LR to HR Adenoma Age 45 Male 3.13E-02 NA NA Correlated set Model calibration 
35 Transition probability: LR to HR Adenoma Age 55 Male 2.06E-02 NA NA Correlated set Model calibration 
36 Transition probability: LR to HR Adenoma Age 65 Male 1.21E-02 NA NA Correlated set Model calibration 
37 Transition probability: LR to HR Adenoma Age 75 Male 1.55E-02 NA NA Correlated set Model calibration 
38 Transition probability: LR to HR Adenoma Age 85 Male 9.27E-03 NA NA Correlated set Model calibration 
39 Transition probability: LR to HR Adenoma Age 35 Female 1.75E-02 NA NA Correlated set Model calibration 
40 Transition probability: LR to HR Adenoma Age 45 Female 2.85E-02 NA NA Correlated set Model calibration 
41 Transition probability: LR to HR Adenoma Age 55 Female 1.45E-02 NA NA Correlated set Model calibration 
42 Transition probability: LR to HR Adenoma Age 65 Female 1.44E-02 NA NA Correlated set Model calibration 
43 Transition probability: LR to HR Adenoma Age 75 Female 1.99E-02 NA NA Correlated set Model calibration 
44 Transition probability: LR to HR Adenoma Age 85 Female 1.14E-02 NA NA Correlated set Model calibration 
45 Transition probability: HR to Cancer Age 35 Male 9.24E-03 NA NA Correlated set Model calibration 
46 Transition probability: HR to Cancer Age 45 Male 1.63E-02 NA NA Correlated set Model calibration 
47 Transition probability: HR to Cancer Age 55 Male 1.81E-02 NA NA Correlated set Model calibration 
48 Transition probability: HR to Cancer Age 65 Male 2.84E-02 NA NA Correlated set Model calibration 
49 Transition probability: HR to Cancer Age 75 Male 5.02E-02 NA NA Correlated set Model calibration 
50 Transition probability: HR to Cancer Age 85 Male 3.52E-02 NA NA Correlated set Model calibration 
51 Transition probability: HR to Cancer Age 35 Female 4.69E-03 NA NA Correlated set Model calibration 
52 Transition probability: HR to Cancer Age 45 Female 2.08E-02 NA NA Correlated set Model calibration 
53 Transition probability: HR to Cancer Age 55 Female 2.72E-02 NA NA Correlated set Model calibration 
54 Transition probability: HR to Cancer Age 65 Female 3.59E-02 NA NA Correlated set Model calibration 
55 Transition probability: HR to Cancer Age 75 Female 6.50E-02 NA NA Correlated set  Model calibration 
56 Transition probability: HR to Cancer Age 85 Female 5.31E-02 NA NA Correlated set Model calibration 
57 Transition probability: Norm to CRC Dukes A Age 15 Male 0 NA NA Correlated set Model calibration 
58 Transition probability: Norm to CRC Dukes A Age 101 Male 5.77E-04 NA NA Correlated set Model calibration 
59 Transition probability: Norm to CRC Dukes A Age 15 Female 0 NA NA Correlated set Model calibration 
60 Transition probability: Norm to CRC Dukes A Age 101 Female 5.74E-04 NA NA Correlated set Model calibration 
61 Transition probability: Dukes Stage A to B undiagnosed 2.93E-01 NA NA Correlated set Model calibration 
62 Transition probability: Dukes Stage B to C undiagnosed 5.54E-01 NA NA Correlated set Model calibration 
63 Transition probability: Dukes Stage C to D undiagnosed 3.50E-01 NA NA Correlated set Model calibration 
64 Proportion CRC_D deaths undiagnosed as a function of age > 75 0.04 NA NA Correlated set Model calibration 
65 Symptomatic presentation with CRC Dukes A 2.03E-02 NA NA Correlated set Model calibration 
66 Symptomatic presentation with CRC Dukes B 1.43E-01 NA NA Correlated set Model calibration 
67 Symptomatic presentation with CRC Dukes C 2.74E-01 NA NA Correlated set Model calibration 
68 Symptomatic presentation with CRC Dukes D 2.50E-01 NA NA Correlated set Model calibration 
69 Symptomatic presentation annual decrement in those aged > 75 3.61E-02 NA NA Correlated set Model calibration 
70 Average number of adenomas present in patient with at least 
one adenoma  
2.3 2.3 2.3 Lognormal Rutter et al 2014 (note based on gFOBT 
screening) 49 
71 Proportion of advanced adenoma classified as high risk 
coefficients: Intercept 
-0.0458 -0.0583 -0.0323 Normal NHS BCSP data 2014/15 (note based on 
gFOBT screening) 40 
 72 Proportion of advanced adenoma classified as high risk 
coefficients: Male 
-0.0463 -0.0553 -0.0379 Normal 
73 Proportion of advanced adenoma classified as high risk 
coefficients: Age 
0.0058 0.0057 0.0059 Normal 
74 Proportion of advanced adenoma classified as high risk 
coefficients: Male * Age 
0.0024 0.0023 0.0024 Normal 
75 FIT Uptake Regression Coefficients: Intercept 0.7096 0.6269 0.8023 Normal UK FIT Pilot (Moss et al 2016) 33 
 76 FIT Uptake Regression Coefficients: Age 65+ -0.1165 -0.1278 -0.1054 Normal 
77 FIT Uptake Regression Coefficients: Age 70+ -0.1192 -0.1206 -0.1178 Normal 
78 FIT Uptake Regression Coefficients: Sex Female 0.1398 0.1310 0.1484 Normal 
79 FIT Uptake Regression Coefficients: Previous non responder -1.8326 -1.8579 -1.8264 Normal 
80 FIT Uptake Regression Coefficients: Incident 1.8795 1.8640 1.8779 Normal 
81 FIT Uptake Regression Coefficients: IMD2 -0.0726 -0.0943 -0.0619 Normal 
82 FIT Uptake Regression Coefficients: IMD3 -0.1508 -0.1625 -0.1278 Normal 
83 FIT Uptake Regression Coefficients: IMD4 -0.2877 -0.3147 -0.2744 Normal 
84 FIT Uptake Regression Coefficients: IMD5 most deprived -0.5978 -0.6162 -0.5978 Normal 
85 FIT Uptake Regression Coefficients: Age 50-54 -0.3647 -0.3659 -0.3635 Normal Scottish FIT Data 2017-1834 
86 FIT Uptake Regression Coefficients: Age 55-59 -0.2516 -0.2519 -0.2512 Normal 
87 FIT Uptake Regression Coefficients: Asian -0.9406 -1.0405 -0.8345 Normal Szczepura et al 2008 35 (note based on 
gFOBT screening England) 
88 FS Uptake Regression Coefficients: Intercept -0.7780 -0.8701 -0.6889 Normal McGregor et al 2016 41 
 89 FS Uptake Regression Coefficients: Males 0.1389 0.0834 0.1939 Normal 
90 FS Uptake Regression Coefficients: IMD1 least deprived 0.7158 0.6141 0.8180 Normal 
91 FS Uptake Regression Coefficients: IMD2 0.5687 0.4713 0.6663 Normal 
92 FS Uptake Regression Coefficients: IMD3 0.3667 0.2738 0.4600 Normal 
93 FS Uptake Regression Coefficients: IMD4 0.1807 0.0899 0.2716 Normal 
94 FS Uptake: Per Year of Age above 55 -0.00163 -0.00223 -0.00108 Normal UKFSST 42, normalised to BCSP mean uptake 
95 FS Uptake: Asian -0.384 -0.673 -0.132 Normal Robb et al 2008 43 (note based on gFOBT 
screening) 
96 Colonoscopy uptake after FIT coefficients: Intercept 1.1691 1.1666 1.1715 Normal NHS BCSP data 2014/15 (note based on 
gFOBT screening) 40 
 
97 Colonoscopy uptake after FIT coefficients: Prevalent screen 0.0993 0.062799 0.1372 Normal 
98 Colonoscopy uptake after FIT coefficients: Female * Prevalent 0.0555 0.0473 0.0638 Normal 
99 Colonoscopy uptake after FIT coefficients: Age -0.00453 -0.00473 -0.00457 Normal 
100 Colonoscopy uptake after FIT coefficients: Age * Prevalent -0.00227 -0.00287 -0.00153 Normal 
101 Colonoscopy uptake after FIT coefficients: Age * Female * 
Prevalent 
-0.0012 -0.0014 -0.001 Normal 
102 Colonoscopy uptake after FS 0.9625 0.950 0.974 Beta UKFSST 42 
103 CTC uptake after FIT 0.9920 0.988 0.995 Beta Plumb et al  2013 45 
104 Surveillance colonoscopy uptake 0.825 NA NA Constant 
 
105 Proportion CTC of all referrals Age 60-61 0.0315 0.028 0.035 Beta NHS BCSP data 2014/15 40 
 106 Proportion CTC of all referrals Age 62-63 0.03697 0.033 0.041 Beta 
107 Proportion CTC of all referrals Age 64-65 0.04495 0.041 0.049 Beta 
108 Proportion CTC of all referrals Age 66-67 0.04424 0.040 0.048 Beta 
109 Proportion CTC of all referrals Age 68-69 0.04700 0.043 0.052 Beta 
110 Proportion CTC of all referrals Age 70-71 0.05309 0.048 0.059 Beta 
111 Proportion CTC of all referrals Age 72-74 0.06071 0.055 0.067 Beta 
112 FIT probability second kit sent 0.02 0.018 0.022 Beta Murphy and Gray 2015 57 
113 FS repeat test rate 0.02065 0.019 0.022 Beta UKFSST 42 
114 Colonoscopy repeat test rate 0.06963 0.068 0.071 Beta NHS BCSP data 2014/15 40 
115 CTC additional investigation rate 0.35445 0.337 0.372 Beta Plumb et al  2013 45 
116 Colonoscopy (with polypectomy) perforation rate 0.00091 0.001 0.001 Beta Rutter et al 2014 49 
117 Colonoscopy (without polypectomy) perforation rate 0.00031 0.000 0.001 Beta Rutter et al 2014 49 
118 FS (with polypectomy) perforation rate 0.000105 0.000 0.000 Beta UKFSST 42 
119 FS (without polypectomy) perforation rate 0 NA NA Constant 
120 CTC perforation rate 0.0002 0.00007 0.00039 Beta Bellini et al 2014 51 
121 Colonoscopy probability of hospitalisation for bleeding 0.0004 0.000 0.001 Beta Rutter et al 2014 49 
122 FS probability of hospitalisation for bleeding 0.000295 0.000 0.000 Beta UKFSST 42 
123 Colonoscopy probability of death following perforation 0.05195 0.015 0.111 Beta Gatto et al 2003 
 124 FS probability of death following perforation  0.06452 0.008 0.172 Beta 
125 CTC probability of death following perforation 0 NA NA Constant Bellini et al 2014 51 
126 Colonoscopy Sensitivity for LR adenomas 0.7651 0.733 0.796 Beta Van Rijn et al 2006 13 
 127 Colonoscopy Sensitivity for HR adenomas 0.9791 0.943 0.997 Beta 
128 Colonoscopy Sensitivity for CRC 0.9656 0.962 0.969 Beta Bressler et al 2007 46 
129 Colonoscopy Specificity 1 NA NA Constant Assumption due to nature of the test 
130 CTC Sensitivity for LR adenomas 0.6274 0.381 1.018 Beta Assumption  based on detection rates 
relative to colonoscopy in Atkin et al. 2013 
47 
131 CTC Sensitivity for HR adenomas 0.8029 0.490 1.277 Beta 
132 CTC Sensitivity for CRC 0.9463 0.606 1.472 Beta 
133 CTC Specificity 0.8812 0.8729 0.8893 Beta Lin et al 2015 48 
134 FS Sensitivity for LR adenomas Male Intercept 0.394 0.369 0.418 Beta Calculated from UKFSST detection rates and 
modelled prevalence 42 135 FS Sensitivity for LR adenomas Male Age Param 0.999 0.988 1.011 Normal 
136 FS Sensitivity for HR adenomas Male Intercept 0.486 0.447 0.526 Beta Calculated from NHS BCSP 2014/15 
detection rates and modelled prevalence 40 
137 FS Sensitivity for HR adenomas Male Age Param 0.988 0.972 1.005 Normal Calculated from UKFSST detection rates and 
modelled prevalence 42 
138 FS Sensitivity for CRC Male Intercept 0.438 0.295 0.581 Beta Calculated from NHS BCSP 2014/15 
detection rates and modelled prevalence 40 
139 FS Sensitivity for CRC Male Age Param 1.034 0.969 1.140 Normal Calculated from UKFSST detection rates and 
modelled prevalence 42 140 FS Sensitivity for LR adenomas Female Intercept 0.321 0.294 0.348 Beta 
141 FS Sensitivity for LR adenomas Female Age Param 0.978 0.964 0.994 Normal 
142 FS Sensitivity for HR adenomas Female Intercept 0.380 0.329 0.431 Beta Calculated from NHS BCSP 2014/15 
detection rates and modelled prevalence 40 
143 FS Sensitivity for HR adenomas Female Age Param 0.947 0.927 0.969 Normal Calculated from UKFSST detection rates and 
modelled prevalence 42 
144 FS Sensitivity for CRC Female Intercept 0.366 0.213 0.519 Beta Calculated from NHS BCSP 2014/15 
detection rates and modelled prevalence 40 
145 FS Sensitivity for CRC Female Age Param 0.916 0.910 1.106 Normal Calculated from UKFSST detection rates and 
modelled prevalence 42 
146 FS Specificity 1 NA NA Constant Assumption due to nature of the test 
147 FIT Sensitivity LR adenomas Males: Power Curve Intercept 0.841 0.7057 1.2074 Beta Calculated from Moss et al. 2016 detection 
rates and modelled prevalence 33 148 FIT Sensitivity LR adenomas Males: Power Curve FIT_Param -0.784 -0.9810 -0.6540 Normal 
149 FIT Sensitivity LR adenomas Males: Age effect > 60 1.034 1.0259 1.0428 Normal Calculated from Zorzi et al. 2018 estimates 
of age effects on detection rates 38 150 FIT Sensitivity LR adenomas Males: Round 2 effect 0.823 0.7362 0.9094 Normal 
151 FIT Sensitivity LR adenomas Females: Power Curve Intercept 0.630 0.5288 0.9050 Beta Calculated from Moss et al. 2016 detection 
rates and modelled prevalence 33 152 FIT Sensitivity LR adenomas Females: Power Curve FIT_Param -0.852 -1.0500 -0.7230 Normal 
153 FIT Sensitivity LR adenomas Females: Age effect > 60 1.026 1.0179 1.0347 Normal Calculated from Zorzi et al. 2018 estimates 
of age effects on detection rates 38 154 FIT Sensitivity LR adenomas Females: Round 2 effect 0.801 0.7166 0.8852 Normal 
155 FIT Sensitivity HR adenomas Males: Power Curve Intercept 1.071 1.0818 1.1313 Beta Calculated from Moss et al. 2016 detection 
rates and modelled prevalence 33 156 FIT Sensitivity HR adenomas Males: Power Curve FIT_Param -0.487 -0.5910 -0.4130 Normal 
157 FIT Sensitivity HR adenomas Males: Age effect > 60 1.027 1.0207 1.0336 Normal Calculated from Zorzi et al. 2018 estimates 
of age effects on detection rates 38 158 FIT Sensitivity HR adenomas Males: Round 2 effect 0.827 0.7626 0.9086 Normal 
159 FIT Sensitivity HR adenomas Females: Power Curve Intercept 1.205 1.2165 1.2731 Beta 
160 FIT Sensitivity HR adenomas Females: Power Curve FIT_Param -0.555 -0.6590 -0.4810 Normal Calculated from Moss et al. 2016 detection 
rates and modelled prevalence 33 
161 FIT Sensitivity HR adenomas Females: Age effect > 60 1.014 1.0072 1.0200 Normal Calculated from Zorzi et al. 2018 estimates 
of age effects on detection rates 38 162 FIT Sensitivity HR adenomas Females: Round 2 effect 0.829 0.7638 0.9100 Normal 
163 FIT Sensitivity CRC Males: Power Curve Intercept 0.526 0.2702 0.8675 Beta Calculated from Moss et al. 2016 detection 
rates and modelled prevalence 33 164 FIT Sensitivity CRC Males: Power Curve FIT_Param -0.083 -0.1450 -0.0540 Normal 
165 FIT Sensitivity CRC Males: Age effect > 60 0.999 0.9852 1.0141 Normal Calculated from Zorzi et al. 2018 estimates 
of age effects on detection rates 38 166 FIT Sensitivity CRC Males: Round 2 effect 0.991 0.8259 1.1768 Normal 
167 FIT Sensitivity CRC Males: Round 3 effect 0.845 0.6758 1.0813 Normal 
168 FIT Sensitivity CRC Females: Power Curve Intercept 0.353 0.1764 0.5820 Beta Calculated from Moss et al. 2016 detection 
rates and modelled prevalence 33 169 FIT Sensitivity CRC Females: Power Curve FIT_Param -0.171 -0.2320 -0.1420 Normal 
170 FIT Sensitivity CRC Females: Age effect > 60 1.008 0.9935 1.0226 Normal Calculated from Zorzi et al. 2018 estimates 
of age effects on detection rates 38 171 FIT Sensitivity CRC Females: Round 2 effect 1.016 0.8467 1.2065 Normal 
172 FIT Sensitivity CRC Females: Round 3 effect 0.863 0.6900 1.1040 Normal 
173 FIT False Positives Males: Power Curve Intercept 0.510 0.3616 0.9747 Beta Calculated from Moss et al. 2016 detection 
rates and modelled prevalence 33 174 FIT False Positives Males: Power Curve FIT_Param -1.020 -1.2930 -0.8470 Normal 
175 FIT False Positives Males: Age effect > 60 1.056 1.0401 1.0714 Normal Calculated from Zorzi et al. 2018 estimates 
of age effects on detection rates 38 176 FIT False Positives Males: Round 2 effect 0.604 0.5952 0.6135 Normal 
177 FIT False Positives Males: Round 3 effect 0.517 0.4994 0.5261 Normal 
178 FIT False Positives Females: Power Curve Intercept 0.538 0.3816 1.0287 Beta Calculated from Moss et al. 2016 detection 
rates and modelled prevalence 33 179 FIT False Positives Females: Power Curve FIT_Param -1.082 -1.3550 -0.9090 Normal 
180 FIT False Positives Females: Age effect > 60 1.056 1.0404 1.0717 Normal Calculated from Zorzi et al. 2018 estimates 
of age effects on detection rates 38 181 FIT False Positives Females: Round 2 effect 0.634 0.6244 0.6436 Normal 
182 FIT False Positives Females: Round 3 effect 0.550 0.5311 0.5596 Normal 
183 Utility decrement age 0.00432 0.00404 0.0046 Normal Ara & Brazier 2010 5 
184 Utility multiplier CRC Yr1 Stage A-C 0.87 0.67 1.07 Normal Djalalov et al 2014 52 
 185 Utility multiplier CRC Yr1 Stage D 0.68 0.42 0.93 Normal 
186 Utility multiplier CRC Yr2+ Stage A-C 0.92 0.76 1.08 Normal 
187 Utility multiplier CRC Yr2+ Stage D 0.73 0.51 0.94 Normal 
188 Annual utility decrement perforation (based on 1 month data) -0.0098 -0.0106 -0.0092 Normal Ara & Brazier 2010 5  
189 Annual utility decrement bleeding (based on 2 week data) -0.0058 -0.0088 -0.0028 Normal Dorian et al. 2014 53 
190 CRC Treatment Costs: Dukes' A & B, Age <64, Year 1 £16,302 £13,264 £19,649 Gamma Laudicella et al. 2016 56, Excess costs 
compared with pre cancer, inflated to 
2017/18 
 
191 CRC Treatment Costs: Dukes' A & B, Age <64, Year 2 £3,826 £3,113 £4,611 Gamma 
192 CRC Treatment Costs: Dukes' A & B, Age <64, Year 3 £3,175 £2,583 £3,827 Gamma 
193 CRC Treatment Costs: Dukes' A & B, Age <64, Year 4 £2,452 £1,995 £2,955 Gamma 
194 CRC Treatment Costs: Dukes' A & B, Age <64, Year 5 £2,206 £1,795 £2,659 Gamma 
195 CRC Treatment Costs: Dukes' A & B, Age <64, Year 6 £1,509 £1,228 £1,818 Gamma 
196 CRC Treatment Costs: Dukes' A & B, Age <64, Year 7 £1,569 £1,276 £1,891 Gamma 
197 CRC Treatment Costs: Dukes' A & B, Age <64, Year 8 £1,438 £1,170 £1,733 Gamma 
198 CRC Treatment Costs: Dukes' A & B, Age <64, Year 9 £1,239 £1,008 £1,494 Gamma 
199 CRC Treatment Costs: Dukes' A & B, Age 65+, Year 1 £15,233 £12,395 £18,361 Gamma 
200 CRC Treatment Costs: Dukes' A & B, Age 65+, Year 2 £3,508 £2,855 £4,229 Gamma 
201 CRC Treatment Costs: Dukes' A & B, Age 65+, Year 3 £2,860 £2,327 £3,447 Gamma 
202 CRC Treatment Costs: Dukes' A & B, Age 65+, Year 4 £2,379 £1,936 £2,867 Gamma 
203 CRC Treatment Costs: Dukes' A & B, Age 65+, Year 5 £2,414 £1,964 £2,910 Gamma 
204 CRC Treatment Costs: Dukes' A & B, Age 65+, Year 6 £2,440 £1,985 £2,941 Gamma 
205 CRC Treatment Costs: Dukes' A & B, Age 65+, Year 7 £2,217 £1,804 £2,672 Gamma 
206 CRC Treatment Costs: Dukes' A & B, Age 65+, Year 8 £2,458 £2,000 £2,962 Gamma 
207 CRC Treatment Costs: Dukes' A & B, Age 65+, Year 9 £2,052 £1,669 £2,473 Gamma 
208 CRC Treatment Costs: Dukes' C & D, Age <64, Year 1 £21,051 £17,128 £25,373 Gamma 
209 CRC Treatment Costs: Dukes' C & D, Age <64, Year 2 £6,895 £5,610 £8,311 Gamma 
210 CRC Treatment Costs: Dukes' C & D, Age <64, Year 3 £4,713 £3,835 £5,681 Gamma 
211 CRC Treatment Costs: Dukes' C & D, Age <64, Year 4 £3,850 £3,132 £4,640 Gamma 
212 CRC Treatment Costs: Dukes' C & D, Age <64, Year 5 £2,748 £2,236 £3,312 Gamma 
213 CRC Treatment Costs: Dukes' C & D, Age <64, Year 6 £2,300 £1,872 £2,772 Gamma 
214 CRC Treatment Costs: Dukes' C & D, Age <64, Year 7 £2,680 £2,181 £3,231 Gamma 
215 CRC Treatment Costs: Dukes' C & D, Age <64, Year 8 £2,055 £1,672 £2,477 Gamma 
216 CRC Treatment Costs: Dukes' C & D, Age <64, Year 9 £1,413 £1,150 £1,704 Gamma 
217 CRC Treatment Costs: Dukes' C & D, Age 65+, Year 1 £16,625 £13,526 £20,037 Gamma 
218 CRC Treatment Costs: Dukes' C & D, Age 65+, Year 2 £5,242 £4,265 £6,318 Gamma 
219 CRC Treatment Costs: Dukes' C & D, Age 65+, Year 3 £4,047 £3,293 £4,878 Gamma 
220 CRC Treatment Costs: Dukes' C & D, Age 65+, Year 4 £3,169 £2,579 £3,820 Gamma 
221 CRC Treatment Costs: Dukes' C & D, Age 65+, Year 5 £2,965 £2,413 £3,574 Gamma 
222 CRC Treatment Costs: Dukes' C & D, Age 65+, Year 6 £2,816 £2,291 £3,394 Gamma 
223 CRC Treatment Costs: Dukes' C & D, Age 65+, Year 7 £1,800 £1,465 £2,170 Gamma 
224 CRC Treatment Costs: Dukes' C & D, Age 65+, Year 8 £2,338 £1,902 £2,818 Gamma 
225 CRC cTreatment Costs: Dukes' C & D, Age 65+, Year 9 £1,818 £1,479 £2,191 Gamma 
226 Cost of FIT invite £7.45 £6.74 £8.16 Uniform Southern Hub screening costings model 
inflated to 2017/18 37 
 
227 Additional cost of FIT performed £1.09 £0.98 £1.19 Uniform 
228 Additional cost of FIT positive result £10.23 £9.26 £11.20 Uniform 
229 Cost of FS invite £5.82 £5.27 £6.37 Uniform 
230 Cost of FS attend diagnostic (not including FS exam) £1.14 £1.04 £1.25 Uniform 
231 Cost of FS attend therapeutic (not including FS exam) £11.37 £10.29 £12.45 Uniform 
232 Cost of FS (without polypectomy) £402 £320 £469 Uniform NHS reference costs 17/18 (IQR estimated 
from 16/17) 54 
 
233 Cost of FS (with polypectomy) £512 £425 £591 Uniform 
234 Cost of COL (without polypectomy) £525 £412 £597 Uniform 
235 Cost of COL (with polypectomy) £641 £515 £730 Uniform 
236 Cost of CTC £121 £97 £141 Uniform 
237 Cost of treating bowel perforation (major surgery) £1,554 £526 £2,258 Uniform 
238 Cost of admittance for bleeding (overnight stay on medical ward) £474 £395 £529 Uniform 
239 Pathology cost £32.75 £13.11 £37.31 Uniform 
Appendix B: Comparison of FIT Detection Rates across Studies  
To investigate the accuracy of the FIT sensitivity estimates based on the UK FIT pilot and to 
investigate trends by age, sex, screening round and FIT threshold, a comparison of UK FIT pilot 
detection with data from other countries was carried out. This included data from the Italian 
screening programme (and from Veneto specifically), the Dutch screening programme, the Swedish 
FIT pilot and a US large scale study 33 38 39 58-61.  
Detection by age 
Only two studies reported detection rates of CRC by age, and one reported detection rates of HR 
adenomas by age. However, we were also able to obtain unpublished information about detection 
rates for all three disease types from the UK FIT pilot through an ODR request. The slope of increase 
appears to be reasonably linear but varies depending between screening studies so for CRC may be 
as small as 0.007% (US data) 60 or as large as 0.039% (Dutch data) 39 per year of age (Figure 26). 
Figure 26: Trends in detection rates following FIT screening by age 
 
The Dutch data was from the first round of a new screening programme, so represented a previously 
unscreened population 39; whilst the US and UK data was from mixed screening populations, 
including individuals who had previously been screened 33 60. Given that lower detection rates are 
observed in subsequent screening rounds, it is likely that the slope represented by the Dutch data is 
the most accurate representation of the age effect, independent from other effects.  
It is important to note that whilst detection rate does appear to increase with age, prevalence also 
increases with age, therefore the sensitivity may not change with age. 
Detection by sex and FIT threshold 
In all screening studies where male and female data is gathered separately, detection rate is higher 
in males than females (Figure 27). As with age, it is unclear how much of this difference is related to 
the difference in underlying prevalence between men and women. 
Figure 27: Trends in detection rates by FIT threshold and sex 
 
The absolute values are very different between studies, which is likely to be due to the different 
average ages represented in each study and the differing mixture of first time screening and 
subsequent screening, in addition to country-specific differences in prevalence and FIT test kit. 
Detection rate decreases as FIT threshold rises, in a non-linear way. The curve appears to be steeper 
for LR adenomas than HR adenomas, and for HR adenomas than CRC. Our previous model used data 
from the prevalent round of the UK FIT pilot only (shown as UK prevalent on the graphs) 33. There is 
extremely high uncertainty around the estimates of CRC detection due to the small numbers 
involved in the pilot. The plots indicate that whilst HR adenoma detection rates for the UK FIT pilot 
prevalent round fall roughly between the separate male and female detection rates for all screening 
rounds in the UK FIT pilot, and close to the male detection rates for Sweden 59, CRC detection rates 
are much lower, indicating that the prevalent round data could be underestimating CRC detection. 
Detection by screening round 
There is large variation between studies in differences by screening round (Figure 28). For the UK 
and Italian studies data is not provided by actual screening round and instead is reported as either 
prevalent (first screen) or incident (subsequent screen) round 33 61; the incident screen has been 
represented on the graph as screen two, but in fact will contain individuals who have been screened 
two or more times.  
The general trend is for detection rates to be reduced in subsequent screening rounds; however, the 
data from the Veneto screening programme 38, which is most comprehensive in terms of providing 
information about a large number of screening rounds, shows the detection rate for CRC flat-lining 
after the third screen, and actually increasing for HR and LR adenoma. This is likely due to 
confounding with age. Indeed, the authors have performed multivariate analysis adjusting for age 
which indicates that CRC detection rates are likely to keep reducing until screening round three, 
whilst HR and LR adenoma detection rates are likely to flat-line after the second screen rather than 
increase. 
 
Figure 28: Trends in detection rates following FIT screening by screening round 
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